US20140178343A1 - Supports and methods for promoting integration of cartilage tissue explants - Google Patents
Supports and methods for promoting integration of cartilage tissue explants Download PDFInfo
- Publication number
- US20140178343A1 US20140178343A1 US13/799,452 US201313799452A US2014178343A1 US 20140178343 A1 US20140178343 A1 US 20140178343A1 US 201313799452 A US201313799452 A US 201313799452A US 2014178343 A1 US2014178343 A1 US 2014178343A1
- Authority
- US
- United States
- Prior art keywords
- tissue
- cartilage
- pieces
- piece
- cartilage tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000845 cartilage Anatomy 0.000 title claims abstract description 290
- 238000000034 method Methods 0.000 title claims abstract description 71
- 230000010354 integration Effects 0.000 title abstract description 8
- 230000001737 promoting effect Effects 0.000 title description 4
- 210000001519 tissue Anatomy 0.000 claims abstract description 270
- 210000004027 cell Anatomy 0.000 claims description 59
- 239000001963 growth medium Substances 0.000 claims description 28
- 210000001612 chondrocyte Anatomy 0.000 claims description 21
- 210000000130 stem cell Anatomy 0.000 claims description 21
- 230000000366 juvenile effect Effects 0.000 claims description 20
- 239000000654 additive Substances 0.000 claims description 12
- 239000003102 growth factor Substances 0.000 claims description 12
- 230000000996 additive effect Effects 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims 4
- 239000012867 bioactive agent Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 44
- 230000007547 defect Effects 0.000 abstract description 32
- 230000008439 repair process Effects 0.000 abstract description 22
- 230000012292 cell migration Effects 0.000 abstract description 8
- 239000000853 adhesive Substances 0.000 description 48
- 230000001070 adhesive effect Effects 0.000 description 48
- 244000309466 calf Species 0.000 description 23
- 239000000560 biocompatible material Substances 0.000 description 22
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 20
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 20
- 210000002744 extracellular matrix Anatomy 0.000 description 20
- 230000003993 interaction Effects 0.000 description 19
- 239000000463 material Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 10
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 230000002648 chondrogenic effect Effects 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 229940072107 ascorbate Drugs 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010041390 Collagen Type II Proteins 0.000 description 3
- 102000000503 Collagen Type II Human genes 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108700039882 Protein Glutamine gamma Glutamyltransferase 2 Proteins 0.000 description 3
- 102100038095 Protein-glutamine gamma-glutamyltransferase 2 Human genes 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940096422 collagen type i Drugs 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 210000000968 fibrocartilage Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000002241 glass-ceramic Substances 0.000 description 3
- 210000003035 hyaline cartilage Anatomy 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 239000004633 polyglycolic acid Substances 0.000 description 3
- 229950008885 polyglycolic acid Drugs 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000012056 semi-solid material Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102100026236 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 201000009859 Osteochondrosis Diseases 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 208000007656 osteochondritis dissecans Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- -1 polypropylene fumarate Polymers 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 2
- 229910052715 tantalum Inorganic materials 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 101001027406 Danio rerio Fibroblast growth factor 8b Proteins 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 1
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 1
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 description 1
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 210000000588 acetabulum Anatomy 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- SSNQAUBBJYCSMY-UHFFFAOYSA-N aigialomycin A Natural products C12OC2CC(O)C(O)C(=O)C=CCC(C)OC(=O)C=2C1=CC(OC)=CC=2O SSNQAUBBJYCSMY-UHFFFAOYSA-N 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000000205 arytenoid cartilage Anatomy 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000005313 bioactive glass Substances 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- LRCVOOBIVXNBIT-NQUDVWKHSA-N bis[2-[(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] butanedioate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]([C@@H](O)C[C@]23C)[C@@H]1[C@@H]3CC[C@]2(O)C(=O)COC(=O)CCC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@H](CCC=3[C@@]4(CCC(=O)C=3)C)[C@@H]4[C@@H](O)C[C@@]21C LRCVOOBIVXNBIT-NQUDVWKHSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000012792 core layer Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000003685 cricoid cartilage Anatomy 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 210000004728 ear cartilage Anatomy 0.000 description 1
- 210000002409 epiglottis Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- SSNQAUBBJYCSMY-KNTMUCJRSA-N hypothemycin Chemical compound O([C@@H](C)C\C=C/C(=O)[C@@H](O)[C@@H](O)C[C@H]1O[C@@H]11)C(=O)C=2C1=CC(OC)=CC=2O SSNQAUBBJYCSMY-KNTMUCJRSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000002263 laryngeal cartilage Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 239000002905 metal composite material Substances 0.000 description 1
- 238000005459 micromachining Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 238000002355 open surgical procedure Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229940058401 polytetrafluoroethylene Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000534 thyroid cartilage Anatomy 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3612—Cartilage, synovial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3852—Cartilage, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/43—Hormones, e.g. dexamethasone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
Definitions
- the present disclosure relates generally to methods and compositions for expanding cartilage tissue explants in vitro, and in particular to a tissue support for promoting expansion and integration of cartilage tissue particles or pieces, and related methods.
- cartilage tissue injury and degeneration of cartilage tissue is a major clinical challenge for several reasons.
- arthritis and other degenerative joint diseases afflict a large proportion of aging populations, which are growing at high rates in most developed countries.
- healing of cartilage tissue is compromised by a lack of direct blood supply.
- cartilage tissue alone is damaged, i.e., in the case of a chondral lesion, local chondrocytes can only achieve limited repair.
- a full-thickness articular cartilage injury, or osteochondral lesion will elicit a complete inflammatory response, but results in poor tissue reformation.
- a surgical approach to repair and prevention of further injury can be the only viable option.
- Total artificial joints have been developed and used as replacements for many years with reasonable success. Total joint replacement is nevertheless costly, invasive, carries certain risks such as blood clots, blood loss and infection, and may not provide complete restoration of function. Additionally, although significant advances have been made over the last few decades in designing robust artificial joints, they do wear out. Total joint replacement in patients younger than about 60 must be carefully considered, given the risk of the artificial joint wearing out.
- Tissue engineering provides an alternative approach to joint repair.
- Engineered tissue including cartilage tissue
- cartilage tissue can now be prepared in vitro and then implanted in an afflicted joint to replace damaged cartilage.
- the technical challenge has been how to engineer a tissue that has the biomechanical properties native to cartilage, and is also biocompatible.
- Various approaches have been tried with differing levels of success.
- One approach is to obtain cells from an acceptable donor source, and seed the cells onto some sort of scaffold that provides needed mechanical support, and then maintain the arrangement in culture with appropriate nutrients and growth factors with the expectation that the seeded cells will mature, or differentiate and mature, to the desired chondrocyte phenotype.
- the present disclosure provides a support for preparing a cartilage composition from a plurality of cartilage tissue pieces, the support comprising a biocompatible material having a surface defining a plurality of tissue anchors separated by a distance sufficient to secure the plurality of tissue pieces to the support at an inter-piece distance of 1 mm or less.
- Each tissue piece has a starting volume less than 1 mm 3 .
- the biocompatible material may comprise a solid material, such as for example at least one trabecular metal, or a semi-solid material such as for example a gel.
- the tissue anchors comprise a plurality of surface features such as pins, barbs, ridges, hooks, posts, recesses and/or apertures in the biocompatible material.
- the support may have a plurality of cartilage tissue pieces coupled to its surface, wherein each cartilage tissue piece is coupled to a tissue anchor on the support so that the tissue pieces are separated by an inter-piece distance of 1 mm or less.
- a cartilage adhesive is optionally applied to the surface defining the plurality of tissue anchors.
- the cartilage adhesive may be applied for example to a plurality of predetermined locations on the surface of tissue anchors, in such manner as to confine the cartilage adhesive to the predetermined locations.
- kits including any support as described herein, and a first container holding a plurality of cartilage tissue pieces.
- the kit may further comprise instructions for securing the plurality of cartilage tissue pieces to the tissue anchors on the support.
- the kit may further comprise a cartilage adhesive, which may be supplied for example in a separate container together with instructions for applying the cartilage adhesive to the surface defining the plurality of tissue anchors on the support.
- the cartilage adhesive may be applied to the surface defining the plurality of tissue anchors on the support.
- the cartilage adhesive may be applied for example to a plurality of predetermined locations on the surface of tissue anchors such that the cartilage adhesive is confined to the predetermined locations.
- the present disclosure provides a tissue culture system for preparing a cartilage composition for repair of a cartilage tissue defect, the tissue culture system including: a support including a biocompatible material having a surface defining a plurality of tissue anchors separated by a distance sufficient to secure a plurality of tissue pieces to the solid support at an inter-piece distance of 1 mm or less; and a plurality of cartilage tissue pieces, each cartilage tissue piece secured to a tissue anchor.
- each cartilage tissue piece may have a volume of less than 1 mm 3 .
- the tissue culture system may comprise any support as described herein.
- the cartilage tissue pieces may comprise for example cartilage tissue obtained from a donor, which may be from a juvenile human donor.
- the cartilage tissue pieces may comprise engineered cartilage tissue.
- the present disclosure provides a method for preparing a cartilage composition for repair of a cartilage tissue defect, including: a) dividing cartilage tissue into a plurality of tissue pieces, each portion having an initial volume of less than 1 mm 3 , and b) maintaining the tissue pieces in a culture medium for a time and under conditions sufficient for each tissue piece to attain an expanded volume of at least 1 mm 3 , wherein the cell culture conditions comprise securing each tissue piece to a support, wherein the support includes a biocompatible material having a surface defining a plurality of tissue anchors separated by a distance sufficient to secure the plurality of tissue pieces to the solid support at an inter-piece distance of 1 mm or less.
- the support may be any of those as described herein.
- the cartilage tissue pieces may comprise for example cartilage tissue obtained from a donor, which may be from a juvenile human donor.
- the cartilage tissue pieces may comprise engineered cartilage tissue.
- the present disclosure provides a method for repair of a cartilage defect, including: a) dividing cartilage tissue into a plurality of tissue pieces, each portion having an initial volume of less than 1 mm 3 , and b) maintaining the tissue pieces in a culture medium for a time and under conditions sufficient for each tissue piece to attain an expanded volume of at least 1 mm 3 , wherein the cell culture conditions comprise securing each tissue piece to a support, wherein the support includes a biocompatible material having a surface defining a plurality of tissue anchors separated by a distance sufficient to secure the plurality of tissue pieces to the solid support at an inter-piece distance of 1 mm or less; c) removing the cartilage composition from the support; and d) implanting the cartilage composition into the cartilage defect.
- the support may be any of those as described herein.
- the cartilage tissue pieces may comprise for example cartilage tissue obtained from a donor, which may be from a juvenile human donor.
- the cartilage tissue pieces may comprise engineered cartilage tissue.
- the method may further comprise maintaining the tissue pieces in the culture medium for a time and under conditions sufficient for at least a first expanded tissue piece to attain an expanded volume sufficient for the first expanded tissue piece to contact at least a second expanded tissue piece.
- the culture conditions may comprise a culture medium including at least one additive from a class of agents selected from the group consisting of: chondrocytes, progenitor cells, stem cells, hormones, growth factors and cytokines.
- the present disclosure provides a method for repair of a cartilage defect, including: a) dividing cartilage tissue into a plurality of tissue pieces, each portion having an initial volume of less than 1 mm 3 ; b) maintaining the tissue pieces in a culture medium for a time and under conditions sufficient for each tissue piece to attain an expanded volume of at least 1 mm 3 , wherein the cell culture conditions comprise securing each tissue piece to a support, wherein the support includes a biocompatible material having a surface defining a plurality of tissue anchors separated by a distance sufficient to secure the plurality of tissue pieces to the solid support at an inter-piece distance of 1 mm or less; and c) implanting and fixing the cartilage composition together with the solid support into the cartilage defect.
- the support may be any of those as described herein.
- the cartilage tissue pieces may comprise for example cartilage tissue obtained from a donor, which may be from a juvenile human donor.
- the cartilage tissue pieces may comprise engineered cartilage tissue.
- the method may further comprise maintaining the tissue pieces in the culture medium for a time and under conditions sufficient for at least a first expanded tissue piece to attain an expanded volume sufficient for the first expanded tissue piece to contact at least a second expanded tissue piece.
- the culture conditions may comprise a culture medium including at least one additive from a class of agents selected from the group consisting of: chondrocytes, progenitor cells, stem cells, hormones, growth factors and cytokines.
- the present disclosure provides a method for preparing a cartilage composition for repair of a cartilage tissue defect, including: a) dividing an amount of cartilage tissue into a plurality of tissue pieces defining a population, each portion having an initial volume of less than 1 mm 3 , and b) maintaining the tissue pieces in a culture medium for a time and under conditions sufficient for each tissue piece to expand so that the average volume of tissue pieces in the population is at least 1 mm 3 .
- the culture medium may comprise any of the additives as described herein.
- the cartilage tissue pieces may comprise for example cartilage tissue obtained from a donor, which may be from a juvenile human donor.
- the cartilage tissue pieces may comprise engineered cartilage tissue may be any of those as described herein.
- the method may further comprise maintaining the tissue pieces in the culture medium for a time and under conditions sufficient for each tissue piece to expand so that the average volume of tissue pieces in the population is at least 1.5 mm 3 .
- the tissue pieces may be maintained in the culture medium for a time and under conditions sufficient for each tissue piece to expand so that the average volume of tissue pieces in the population is at least 2.0 mm 3 .
- each tissue piece may be positioned on a culture surface at an inter-piece distance of 1 mm or less.
- the tissue piece may be secured to the culture surface at an inter-piece distance of 1 mm or less as it is positioned.
- the cartilage adhesive is optionally applied to an interface between each tissue piece and the culture surface.
- the cartilage adhesive may be applied for example to a plurality of predetermined locations on the surface, in such manner as to confine the cartilage adhesive to the predetermined locations.
- the method may further comprise maintaining the tissue pieces in the culture medium for a time and under conditions sufficient for at least a first expanded tissue piece to attain an expanded volume sufficient for the first expanded tissue piece to contact at least a second expanded tissue piece.
- the culture conditions may comprise a culture medium including at least one additive from a class of agents selected from the group consisting of: chondrocytes, progenitor cells, stem cells, hormones, growth factors and cytokines.
- the present disclosure provides a cartilage composition for repair of a cartilage tissue defect, wherein the cartilage composition includes a plurality of expanded cartilage tissue pieces defining a population, wherein each tissue piece in the population is expanded from an initial volume of less than 1 mm 3 to an expanded volume such that the population of expanded cartilage tissue pieces has an average expanded volume of at least 1 mm 3 .
- the average volume of expanded cartilage tissue pieces in the population is for example at least 1.5 mm 3 .
- the average volume of expanded cartilage tissue pieces in the population is at least 2.0 mm 3 .
- each expanded tissue piece in the population contacts at least one other expanded tissue piece.
- the cartilage tissue pieces may comprise for example cartilage tissue obtained from a donor, which may be from a juvenile human donor.
- the cartilage composition may further comprise a culture medium including at least one additive from a class of agents selected from the group consisting of: chondrocytes, progenitor cells, stem cells, hormones, growth factors and cytokines.
- the expanded cartilage tissue pieces are obtained by a) dividing an initial amount of cartilage tissue into a plurality of cartilage tissue pieces defining a population, each portion having an initial volume of less than 1 mm 3 , and b) and maintaining the cartilage tissue pieces in a culture medium for a time and under conditions sufficient for each tissue piece to expand so that the average volume of tissue pieces in the population is at least 1 mm 3 .
- the step of obtaining the expanded tissue pieces further comprise before step (b), the step of positioning each tissue piece on a culture surface at an inter-piece distance of 1 mm or less.
- the present invention also provides use of the cartilage composition as disclosed herein to repair a cartilage defect in a subject in need thereof.
- the present disclosure provides a method for repair of a cartilage defect, including: implanting and fixing into the cartilage defect a cartilage composition including a plurality of expanded cartilage tissue pieces defining a population, wherein each tissue piece in the population was expanded from an initial volume of less than 1 mm 3 to an expanded volume such that the population of expanded cartilage tissue pieces has an average expanded volume of at least 1 mm 3 .
- the average volume of expanded cartilage tissue pieces in the population is at least 1.5 mm 3 .
- the average volume of expanded cartilage tissue pieces in the population is at least 2.0 mm 3 .
- at least a first expanded tissue piece contacts at least a second expanded tissue piece.
- each expanded cartilage tissue piece in the population contacts at least one other expanded tissue piece.
- the cartilage tissue pieces may comprise for example cartilage tissue obtained from a donor, which may be from a juvenile human donor.
- the cartilage tissue pieces may comprise engineered cartilage tissue may be any of those as described herein.
- the cartilage composition in the method may further comprise a culture medium including at least one additive from a class of agents selected from the group consisting of: chondrocytes, progenitor cells, stem cells, hormones, growth factors and cytokines.
- FIG. 1 is a perspective, top view of a first exemplary tissue support with enlarged view of tissue anchors in form of small pins projecting from the upper surface of the tissue support.
- FIG. 2 is a cross-sectional view of a second exemplary tissue support, showing tissue anchors in the form of recessions on the upper surface of the tissue support.
- FIG. 3 is a cross-sectional view of the first exemplary tissue support of FIG. 1 , showing small tissue pieces placed on the pins.
- FIG. 4 is a cross-sectional view of the second exemplary tissue support of FIG. 2 , showing small tissue pieces placed in the recessions.
- FIG. 5 is a series of photomicrographs showing expansion of calf and human juvenile cartilage explants in culture.
- FIG. 6 is a series of photomicrographs showing non-uniform expansion of cultured cartilage explants.
- FIG. 7 is a photomicrograph showing the structural interactions observed between cultured calf cartilage pieces at day 5 of culture (20 ⁇ ), when maintained at an inter-piece distance of 1 mm.
- FIG. 8 is a photomicrograph showing the structural interactions observed between cultured human juvenile cartilage pieces at day 5 of culture (5 ⁇ ), when maintained at an inter-piece distance of 1 mm.
- FIG. 9 is a photomicrograph showing results obtained with calf cartilage explants that were cultured with different inter-piece distances, showing structural integration of two neighboring pieces only when they the inter-piece distance was no greater than 1 mm.
- FIG. 10 is a photomicrograph showing results obtained with calf cartilage explants during an initial culture phase in which inter-piece interactions including simultaneous cell migration into the inter-piece area and production of ECM. Newly formed ECM along with the cells embedded inside can be seen as a bridge between the two neighboring pieces which “glues” the cells together.
- FIG. 11 is a series of photomicrographs showing the formation of inter-piece interactions of human juvenile cartilage explants.
- the cells migrated into the inter-piece area and produce ECM simultaneously.
- the newly formed ECM along, with the embedded cells, can be seen as a bridge between the two pieces which “glues” the cells together.
- Inter-piece interactions enclosed by the red circle in A (5 ⁇ ) are shown in B (20 ⁇ ).
- Inter-piece interactions enclosed by the red circles in C (5 ⁇ ) are shown in D and E (20 ⁇ ).
- FIG. 12 is a pair of photomicrographs of calf cartilage explants showing structural inter-piece interactions over time, which became denser and stringer over time. The newly formed interactions contain both cells and ECM.
- FIG. 13 is a series of photomicrographs of human juvenile cartilage explants showing the inter-piece interactions over time, which became denser and stronger over time.
- the newly formed interactions contain both cells and ECM.
- FIG. 14 is a pair of photomicrographs of calf cartilage explants showing structural inter-piece interactions over time, which became thicker and wider over time. Inter-piece interactions are highlighted by the red circle.
- FIG. 15 is a series of photomicrographs of histologically stained cultured calf cartilage explants at 10 weeks of culture, in which newly formed inter-piece interaction areas are enclosed by the red circles.
- A the two calf cartilage pieces at 10 weeks of culture before histology staining
- F Alcian blue staining
- G Safranin O Staining
- C and E: show the cell migration out of the edges of the original calf cartilage pieces.
- FIG. 16 is a pair of photomicrographs showing cultured cartilage pieces positioned at an inter-piece distance of greater than 1 mm were mainly surrounded by the migrated cells.
- A calf cartilage explants (10 ⁇ )
- B human juvenile cartilage explants (10 ⁇ ).
- FIG. 17 is a pair of photomicrographs of results after 10 weeks of culture, showing cells that migrated out of human juvenile cartilage explant proliferated and accumulated next to the original tissue pieces, where they piled up as multiple layers and reached approximately the same height of the cartilage pieces.
- FIG. 18 is a series of photomicrographs showing effects of cartilage harvesting locations: A: trochlea, B: trochlea groove, C: femoral condyle, D: central tibial plateau and E: peripheral tibial plateau. Pictures were taken on day 35 of culture.
- FIG. 19 is a photomicrograph showing results obtained with calf cartilage explants of different sizes.
- FIG. 20 is a series of photomicrographs showing migrated cells from calf cartilage explants having different phenotypes, on TC and ULA plates.
- A the bottom layers of cell attached to the bottom area of TC plates on day 35 of culture (10 ⁇ ).
- B The initial formation of cell cluster from individual cells on ULA plates on day 35 of culture (10 ⁇ ).
- C Multiple layers of cells formed on the bottom of TC plates on day 120 of culture. The top layer of cells showed un-stretched round shape (10 ⁇ ).
- D More and bigger cell clusters were formed on ULA plates on day 120 of culture, the majority of cells inside the cluster showed round shape (20 ⁇ ).
- tissue pieces when maintained in vitro under culture conditions, will expand and structurally integrate with neighboring tissue pieces when maintained at an inter-piece distance of 1 mm or less than 1 mm.
- inter-piece distance is meant that distance from an outside surface of one tissue piece to the closest outside surface of a second tissue piece adjacent to the first tissue piece.
- Exemplary tissue pieces have a volume of less than about 1 mm 3 , and may be of many possible shapes, e.g., cubes, cylinders, ovoids, and the like, which may be produced according to the method of preparing the pieces from a tissue source.
- An outside surface of a tissue piece may therefore be substantially linear or arcuate, depending on the shape of the tissue piece.
- tissue pieces may be substantially cuboid, with substantially linear outer surfaces, and have a volume of less than about 1 mm 3 , e.g., dimensions of less than approximately 1 mm on each side.
- tissue pieces may be substantially cuboid, with substantially linear outer surfaces, and have a volume of less than about 1 mm 3 , e.g., dimensions of less than approximately 1 mm on each side.
- the newly formed ECM forms new inter-piece tissue that binds neighboring pieces together. Additionally, more cells migrate over time onto the inter-piece tissue, and cells already embedded inside the ECM also continue to proliferate. As a result, the ECM becomes denser, and the volume of the inter-piece tissue, which consists of multiple layers of ECM and cells embedded therein, increases. The increase in tissue volume is reflected in an increase in height, width and/or length of the inter-piece tissue, which also becomes structurally integrated with the neighboring tissue pieces. Particularly surprising is the finding that the thus newly formed inter-piece tissue exhibits structure that is comparable to that of the original cartilage tissue, based on gross and histological evaluation. The expanded tissue thus provides a new source for a cartilage composition that can be used for cartilage repair.
- the term “about” refers to approximately a +/ ⁇ 10% variation from the stated value. It is to be understood that such a variation is always included in any given value provided herein, whether or not it is specifically referred to.
- biocompatible material refers to a synthetic or natural material that can be used to replace part of a living system or to function when in close contact with living tissue.
- cartilage refers to an avascular tissue, having chondrocytes encapsulated within an extracellular matrix.
- cartilage tissue may be donor cartilage tissue or engineered cartilage tissue.
- Cartilage encompasses articular cartilage, hyaline cartilage, neocartilage (Adkisson, H. D. et al., Clin. Orthop. 391S: S280-S294, 2001; and U.S. Pat. Nos.
- cartilage can also comprise chondrocytes differentiated from precursor cells such as mesenchymal stem cells.
- cartilage adhesive refers to molecular species or mixtures of species which promote adhesion of cartilage tissue or chondrocytes of the cartilage tissue to a surface, by acting as a binding agent (e.g., a glue) and/or by promoting adhesion-forming activity of cells.
- a cartilage adhesive can be used as a binding agent (e.g., a glue) at the interface between cartilage or chondrocytes thereof and a surface.
- cartilage defect refers to a structural and/or biological imperfection in cartilage tissue such as but not limited to a break, tear, void or other disintegration of the tissue, which is caused by a disease, injury or condition and which can benefit from cartilage repair, replacement, or augmentation, such as, in non-limiting example, athletic injury, traumatic injury, congenital disorders, osteoarthritis and joint degeneration from aging.
- chondrogenic cell refers to chondrogenic progenitor cells (CPCs), the further differentiation of which results in chondrocytes.
- Chondrogenic cells can come from a variety of sources. Generally, the chondrogenic cells can be isolated from an articular cartilage or a fibrocartilage. Chondrogenic cells from a fibrocartilage can be obtained from costal, nasal, auricular, tracheal, epiglottic, thyroid, arytenoid and cricoid cartilages. Alternatively, cells from fibrocartilage can be obtained from tendon, ligament, meniscus and intervertebral disc.
- chondrogenic cells may refer to partially differentiated progenitor cells destined to be chondrocytes or chondrogenic stem cells that are more primitive.
- the chondrogenic stem cells can be derived from a tissue such as placenta, umbilical cord, bone marrow, skin, muscle, fat, periosteum, and perichondrium.
- subject refers to a mammal, which may be a human or a non-human mammal such as but not limited to a horse, a dog, a cat, a non-human primate such as a monkey or ape, a rabbit, a rat, a mouse, or a pig.
- trabecular metal encompasses any biocompatible metal or metal composite having interconnecting pores and at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 85% porosity by volume.
- Exemplary such metals have pores of about 200 ⁇ m-700 ⁇ m in diameter, and preferably 400 ⁇ m-600 ⁇ m in diameter.
- Descriptions of trabecular metal, as well as various methods of making trabecular metal of various pore sizes are known in the art.
- An exemplary such material is a tantalum composite sold as Trabecular Metal® by Zimmer, Inc.
- the present disclosure provides a support for preparing a cartilage composition from a plurality of cartilage tissue pieces, the support including a biocompatible material having a surface defining a plurality of tissue anchors separated by a distance sufficient to secure the plurality of tissue pieces to the support at an inter-piece distance of 1 mm or less.
- Tissue pieces of varying initial volumes may be used.
- a tissue piece may for example have a starting volume of about 1 mm 3 , or less than about 1 mm 3 , or more than about 1 mm 3 .
- tissue pieces having an initial average volume of less than 1 mm 3 , maintained at an inter-portion distance of 1 mm or less can expand as described herein to attain an average volume of at least 1.5 mm 3 or 2.0 mm 3 and thereby integrate with surrounding pieces. It should nevertheless be appreciated that if the tissue pieces are cultured under more favorable expansion conditions, for example by the addition of growth factors to the culture system, the tissue pieces may attain a greater volume within a given period of time, and thereby integrate two neighboring pieces that are maintained at a distance of more than 1 mm apart.
- an exemplary tissue piece size is about 1 mm 3 , or less than about 1 mm 3
- the initial tissue size (volume) could be larger than about 1 mm 3 and still suitably expand as described herein.
- Tissue pieces may vary in shape and may be for example substantially spherioid, cuboid, cylindrical, or ovoid. It should be understood that the shape of the tissue pieces will depend in part on the method used to prepare tissue pieces from the donor tissue.
- a non-limiting exemplary tissue piece is substantially cuboid and has a starting volume less than about 1 mm 3 , e.g., dimensions of less than approximately 1 mm on each side.
- the biocompatible material may comprise a solid material, such as for example at least one trabecular metal, or a semi-solid material such as for example a gel.
- the tissue anchors comprise a plurality of surface features such as pins, barbs, ridges, hooks, posts, recesses and/or apertures in the biocompatible material.
- the support may have a plurality of cartilage tissue pieces coupled to its surface, wherein each cartilage tissue piece is coupled to a tissue anchor on the support so that the tissue pieces are separated by an inter-piece distance of 1 mm or less.
- a cartilage adhesive is optionally applied to the surface defining the plurality of tissue anchors.
- the cartilage adhesive may be applied for example to a plurality of predetermined locations on the surface of tissue anchors, in such manner as to confine the cartilage adhesive to the predetermined locations.
- the tissue anchors may be provided solely as adhesive spots in predetermined locations on an otherwise featureless surface of the support.
- tissue supports for maintaining tissue pieces at an inter-piece distance of 1 mm or less.
- a tissue support 100 is generally made of a biocompatible material 102 having a surface 104 defining multiple tissue anchors 106 for securing tissue pieces to support 100 .
- the tissue anchors may take the form of any of a number of suitable surface projections from surface 104 .
- each tissue anchor is a pin 108 .
- Other projecting forms suitable for securing tissue pieces can be used, such as but not limited to barbs, ridges, hooks, or straight or curved posts.
- the tissue anchors may generally take the form of depressions or recesses 110 in surface 104 , as shown in FIG. 2 , or they may consist of apertures through biocompatible material 102 .
- Such depressions, recesses or apertures through biocompatible material 102 may for example be configured with a shape and/or dimensions approximately matched to the shape and/or dimensions of the tissue pieces.
- apertures for receiving substantially spherical tissue pieces may be configured as round holes through biocompatible material 102 , having a diameter approximating the average diameter of the tissue pieces.
- the tissue anchors may consist solely of defined adhesive locations (not shown) on surface 104 , wherein the adhesive locations are created by applying a cartilage adhesive to defined locations, e.g., as “dots” or “spots” of adhesive, on surface 104 , which is otherwise free of physical anchors such as projecting anchors, or depressions or apertures.
- the multiple tissue anchors are distributed substantially uniformly across surface 104 in any configuration such that each anchor is positioned at a maximum distance of about 1 mm to about 2 mm from at least one neighboring tissue anchor.
- the distribution of tissue anchors across surface 104 may be according to any regular or irregular pattern, provided that each anchor is no more than a maximum distance of about 1 mm to about 2 mm from at least one neighboring anchor, so that each tissue piece is able to expand and integrate with at least one neighboring piece. It will be appreciated that any distribution pattern that maximizes packing of the initial tissue pieces across surface 104 within the specified maximum distance, and thus any regular, geometric distribution pattern of the tissue anchors, will be preferred.
- tissue anchor dimensions may suitably vary depending on the size and/or density of the tissue piece(s), and on the shape of the anchor.
- Tissue anchors should be sized and shaped such that the act of applying and securing a tissue piece to an anchor will not obliterate most or all of the tissue piece.
- a tissue piece having a generally cuboid shape of about 1 mm on a side, or a thinner tissue piece of about 1 mm in length and 1 mm in width may be anchored to the support surface using an anchor configured as a straight pin, with a largest diameter of about 50-500 microns.
- Anchors for tissue pieces larger than about 1 mm on a side may be appropriately sized to have a larger diameter or other cross-sectional area.
- tissue support shape may be varied to approximate the shape of an anatomical target, such that the tissue generated on the support in vitro will approximate the target anatomical shape.
- a support may have an arcuate shape such that the resulting tissue is appropriately shaped to be implanted at the acetabulum, head of the femur or other curved anatomic surface.
- a support may have a generally pyramidal shape for implantation at a talar dome lesion or fracture. Other shapes suitably adapted for other anatomical targets are also contemplated.
- Each tissue piece is secured to surface 104 by applying, e.g. manually, each piece at its approximate center onto a tissue anchor, as shown in FIG. 3 and FIG. 4 .
- tissue anchors that are separated by a distance of about 1 mm will provide an inter-piece distance of about 0.0 mm, e.g., the initial tissue pieces are in contact or very close to contacting neighboring piece(s).
- Tissue anchors that are separated by a distance of about 2 mm will provide an inter-piece distance of about 1.0 mm, i.e., a distance at which the initial tissue pieces are at or close to the maximum inter-piece distance, according to the findings and methods disclosed herein.
- Each piece is secured in position on an anchor by piercing, lancing or hooking the piece onto a projecting anchor on surface 104 , or by depositing (e.g., by manually pressing) each piece at least partially into an anchor that is a depression, recess or anchor in surface 104 .
- the cartilage adhesive is applied, e.g. by manually “dotting” or “spotting” the cartilage adhesive onto surface 104 in selected locations, applying a population of tissue pieces to surface 104 , waiting for a period of time sufficient for a subset of the tissue pieces to bind or adhere to the selected locations, and then removing all unbound or non-adhered tissue pieces, e.g. by washing or rinsing the unbound pieces way.
- a cartilage adhesive is optionally used to further secure each tissue piece in position on the tissue support, for example by the applying cartilage adhesive to an interface between each tissue piece and a tissue support surface.
- a cartilage adhesive may be applied to tissue anchor surfaces, or to inter-anchor regions of the tissue support, or to both.
- Use of a cartilage adhesive may be desired for example when the support has anchors that do not otherwise secure the tissue pieces to the support through physical means such as piercing or hooking, e.g. depressions or apertures.
- cartilage adhesive may be used with any of the anchor forms described herein.
- a cartilage adhesive may be any biologically compatible composition capable of adhering to both biocompatible material 102 and the tissue pieces.
- a cartilage adhesive may be, but is not limited to, a fibrin-based adhesive, a collagen-based adhesive or a combination thereof.
- a cartilage adhesive can comprise for example tissue trans-glutaminase, hyaluronic acid, collagen type I, collagen type II, a chemically cross-linked collagen, fibrin, albumin, gelatin, elastin, silk, demineralized bone matrix, polyethylene oxide, polyethylene glycol, polyvinyl alcohol, polypropylene fumarate or a combination thereof as described elsewhere, or a hydrogel. (See, e.g., Jurgensen et al., J.
- a vertebrate-derived component of a cartilage adhesive such as tissue trans-glutaminase, hyaluronic acid, collagen type I, collagen type II, fibrin, albumin, gelatin, or elastin, or demineralized bone matrix, can be autologous, allogeneic, or xenogeneic to a mammalian recipient of an implant, such as a human patient in need of treatment.
- a protein or polypeptide component of a cartilage adhesive such as tissue trans-glutaminase, hyaluronic acid, collagen type I, collagen type II, fibrin, albumin, gelatin, or elastin
- tissue trans-glutaminase hyaluronic acid
- collagen type I collagen type II
- fibrin fibrin
- albumin albumin
- gelatin or elastin
- a protein or polypeptide component of a cartilage adhesive such as tissue trans-glutaminase, hyaluronic acid, collagen type I, collagen type II, fibrin, albumin, gelatin, or elastin
- a naturally-occurring source such as an animal or human donor
- molecular biological methods well known to skilled artisans such as expression of a gene or cDNA encoding the protein in transformed or transfected cells (see, e.g., Sambrook, J., et al., Molecular Cloning: A Laboratory Manual, 3rd ed. Cold Spring Harbor
- a cartilage adhesive may also comprise one or more cell-attachment factors, such as collagen I or collagen IV, fibronectin, laminin, or poly-lysine, or another commercially available cell attachment factor, inasmuch as chondrocytes are exposed at a surface of a tissue piece.
- cell-attachment factors such as collagen I or collagen IV, fibronectin, laminin, or poly-lysine, or another commercially available cell attachment factor, inasmuch as chondrocytes are exposed at a surface of a tissue piece.
- the cartilage adhesive may be applied for example to a plurality of predetermined locations on the surface of tissue anchors, in such manner as to confine the cartilage adhesive to the predetermined locations.
- the cartilage adhesive may be applied for example directly to any projecting anchor such as a pin, hook or barb, to complement the physical coupling of each tissue piece to such an anchor.
- the cartilage adhesive may be applied to the surface of the support surrounding an anchor that is a depression, recess or aperture through the support, or to the depression or recess itself, or to the internal walls of an aperture, or any combination thereof.
- Biocompatible material 102 may comprise any of a number of materials suitable for use in tissue culture and may comprise a material or materials that enhance cell migration, cell attachment and the formation of extracellular matrix of the cells.
- Such materials include for example a metal, either a single metal or a combination of metals. Accordingly, titanium, cobalt, chromium, platinum, iridium, niobium or tantalum may be used, or any alloy thereof, and also stainless steel. Any metal may be a trabecular metal.
- Ceramics may be used, such as but not limited to calcium hydroxylapatite (dense or porous), bioactive glass (e.g., Bioglass®, Ceravital®), bioactive glass-ceramics (A/W glass-ceramic such as Cerabone®, or dense or porous hydroxyapatite), and workable glass-ceramics and phosphates glasses such as Bioverit® I, II and III.
- suitable biocompatible materials also include biopolymers such as poly-lactic acid (PLA), poly-glycolic acid (PGA), Dacron, collagen, PET (poly-ethylene terephthalate), poly-carbonate, poly-tetrafluoroethylene, and co-polymers of PLA and PGA.
- the biocompatible material may comprise a semi-solid material such as for example a gel, such as a hydrogel, or a wax.
- a biocompatible material may include any combination of any of the above, for example but not limited to a layered configuration with one or more core layers of certain material(s) covered by a surface layer of a different material.
- protein layers may be attached to the surface of any material to promote cell attachment.
- tissue support though illustrated in the accompanying drawings as a substantially flat surface with tissue anchors projecting therefrom, may alternatively be configured in any shape such as one specially adapted for implantation into a particular defect, provided only that the shape includes at least one surface capable of bearing multiple tissue anchors.
- certain biocompatible materials suitable as the support material and also having some amount of flexibility, such as gels, waxes and any composite material containing a gel or wax may be especially suitable for in vitro applications.
- Methods for manufacturing a tissue support as described will depend on the material(s) selected and desired shape of the support, and are well known in the art.
- Precision manufacturing services are provided by many contract manufacturing organizations specializing in the manufacture of medical devices which provide manufacturing services including casting, extrusion, molding, and precision machining including milling and micromachining techniques such as microfinishing (deburring and polishing).
- the present disclosure encompasses methods for preparing a cartilage composition by dividing cartilage tissue into a plurality of tissue pieces, each having an initial volume of less than 1 mm 3 , and maintaining the tissue pieces in a culture medium for a time and under conditions sufficient for each tissue piece to attain an expanded volume of at least 1 mm 3 or more, e.g. at least 1.5 mm 3 or at least 2 mm 3 .
- the present disclosure also provides a method for repair of a cartilage defect by implanting and fixing into the cartilage defect a cartilage composition including a plurality of expanded cartilage tissue pieces having an average expanded volume of at least 1 mm 3 , at least 1.5 mm 3 or at least 2 mm 3 .
- sufficient time for each tissue piece to attain an expanded volume of at least 1 mm 3 or more is at least about 4 days, and can be for example as long as 14 days. While each piece may not actually attain an expanded volume of at least 1 mm 3 or more in the time period, it is contemplated that a minimum time of about 4 days under appropriate culture conditions is sufficient for at least 10%, 20%, 30%, 40%, 50%, 60, 70%, 80%, 90% or 100% of the tissue pieces to attain an expanded volume of at least 1 mm 3 or more. It should be understood that due to variation among pieces including differences in the microclimate, not all pieces will expand and integrate with neighboring pieces at the same rate. Longer periods of time will result in more pieces attaining a minimum expanded volume, and also more pieces that attain an expanded volume greater the minimum expanded volume.
- Tissue culture conditions suitable for expanding and maintaining cartilage tissue as described herein are well known in the art.
- tissue including actively dividing cells is grown and maintained at an appropriate temperature which for mammalian cells, is at or about 37° C., and using a gas mixture of 5% CO 2 .
- tissue may be maintained for example in an incubator, in a growth medium.
- the formulation for a suitable growth medium may be varied along several factors: pH, glucose concentration, number and amount of growth factors, and presence of other nutrients. Growth factors derived from a number of sources may be used, including whole animal serum such as bovine calf serum.
- a suitable growth medium is, in non-limiting example, DMEM/F12 medium supplemented with fetal bovine serum (FBS).
- a serum-free medium or a chemically defined medium may be used, which may be supplemented with ascorbate and/or glutamine.
- a suitable such growth medium is, in non-limiting example, HL-1 serum-free medium (Lonza Walkersville, Inc., Walkersville, Md.) supplemented with at least about 2 mM or more of glutamine, and about 50 to about 100 ⁇ g/ml ascorbate.
- a culture medium may include at least one additive from a class of agents selected from the group consisting of: chondrocytes, progenitor cells, stem cells, hormones, growth factors and cytokines, or any composition containing such an additive or additives such as platelet rich plasma (PRP).
- PRP platelet rich plasma
- Progenitor cells and stem cells include for example cartilage progenitor cells or bone marrow cells.
- Growth factors and cytokines may be any from among the many known such agents, including but not limited to ECGF (Endothelial Cell Growth Factor), VEGF 168, VEGF 145, VEGF 121, aFGF (Fibroblast Growth Factor, acidic), bFGF (Fibroblast Growth Factor, basic), EGF (epidermal growth factor), PDGF (platelet derived growth factor), FGF-10, FGF-4, FGF-5, FGF-6, FGF-8b, FGF-9, IGF (insulin-like growth factor), KGF (Keratinocyte Growth Factor), TGF- ⁇ (transforming growth factor ⁇ ), collagen, hypothemycin, interleukin-8 (IL-8), and IL-13.
- ECGF Endothelial Cell Growth Factor
- VEGF 168 VEGF 145
- VEGF 121 aFGF (Fibroblast Growth Fact
- the hormones may be chosen from hydrocortisone, insulin, triiodothyronine, thyroxine, Retinyl acetate, Activin A, (2-Hydroxypropyl)- ⁇ -cyclodextrin, Methyl- ⁇ -cyclodextrin, and Hydrocortisone 21-hemisuccinate.
- the cell culture conditions may include for example maintaining the tissue pieces at an inter-piece distance of 1 mm or less. This may be accomplished for example by securing each tissue piece to a tissue support as described herein.
- tissue support 100 has a plurality of cartilage tissue pieces coupled to its surface via the tissue anchors on support 100 , such that the tissue pieces are separated by an inter-piece distance of 1 mm or less. It should be understood however that other means for maintaining the inter-piece distance are encompassed by the present disclosure.
- the methods further encompass methods for repairing a cartilage defect, for example in a subject.
- the cartilage expansion methods as described herein may be applied for example to methods to prepare a cartilage composition in vitro for subsequent implantation into a subject for repair of a cartilage tissue defect in the subject.
- the approach can be adapted to methods to generate a cartilage composition in vivo in the subject.
- a method for repair of a cartilage defect may include for example producing in vitro a cartilage composition on a support, from cartilage pieces each having an initial volume of less than 1 mm 3 as described herein, by expanding the initial cartilage pieces in vitro to an expanded volume of at least 1 mm 3 , followed by removing the resulting cartilage composition from the support, and then implanting and fixing the cartilage composition into the cartilage defect.
- a method for repair of a cartilage defect may include producing in vitro a cartilage composition on a support as described herein, and then implanting the cartilage composition together with the solid support into the cartilage defect, and closing the surgical opening such that the tissue pieces expand in vivo to an expanded volume of at least 1 mm 3 or more. It will be appreciated that the latter alternative favors the use of a tissue support that is either prepared from a flexible material or materials, or is configured in a shape that fits closely with the defect being repaired.
- a method for preparing a cartilage composition for repair of a cartilage tissue defect may involve a population of tissue pieces, wherein a) an amount of cartilage tissue is divided into a plurality of tissue pieces defining a population, each portion having an initial volume of less than 1 mm 3 , and b) the tissue pieces are maintained in a culture medium for a time and under conditions sufficient for each tissue piece to expand so that the average volume of tissue pieces in the population is at least 1 mm 3 .
- the tissue pieces may be maintained for a time and under conditions sufficient for each tissue piece to expand such that the average volume of tissue pieces in the population is greater than 1 mm 3 , for example at least 1.5 mm 3 , or at least 2.0 mm 3 .
- This approach may include positioning each tissue piece on a culture surface, such as a tissue support as described herein, at an inter-piece distance of 1 mm or less before the expansion step (b).
- a culture surface such as a tissue support as described herein
- Each such tissue piece may be secured to such a support by means of an anchor or a cartilage adhesive, both as described herein, or a combination thereof.
- the tissue pieces which may be a population of tissue pieces, may be maintained for a time and under conditions sufficient for at least one, or more, of the tissue pieces to expand and thereby attain an expanded volume that is sufficient for the tissue piece(s) to contact at least one neighboring tissue piece that has also expanded.
- a starting population of tissue pieces is maintained for a time and under conditions sufficient for a simple majority if tissue pieces in the population, or for as many as all tissue pieces in the population, or for any number of tissue pieces in between a simple majority and the entire population, to expand and thereby attain an expanded volume that is sufficient for the tissue piece(s) to contact at least one neighboring tissue.
- repair is meant a surgical repair such as an open surgical procedure (arthrotomy) or an arthroscopic procedure by which the in vitro prepared cartilage composition is implanted into the defect, with or without the tissue support.
- the cartilage composition, or cartilage composition together with the support may be fixed in the defect using a mechanical fastener such as a staple, screw, pin or the like, or a tissue adhesive such as for example any adhesive described elsewhere herein.
- cartilage tissue pieces or pieces may, without limitation, be prepared from donor or engineered cartilage tissue such as neocartilage, or a combination thereof.
- Source tissue may be allogeneic to, autologous to, and/or xenogeneic to a mammalian recipient such as a human patient.
- Cartilage tissue pieces may comprise for example, hyaline cartilage or any tissue including chondrocytes having the potential to generate hyaline cartilage, but not necessarily organized into histologically recognizable cartilage.
- Donor cartilage tissue includes, for example, articular joint cartilage including knee joint and hip joint cartilage, tracheal cartilage, laryngeal cartilage, costal cartilage, epiphyseal plate cartilage, and any combination thereof. It will be understood that the methods and devices can be utilized to produce cartilage composition of various sources to meet the needs for treating cartilage defects of any origin.
- Donor cartilage tissue may be obtained from a live or a deceased donor.
- Donor cartilage tissue may be obtained for example from a juvenile donor, for example a donor less than fifteen years of age, preferably fourteen years of age or younger, and more preferably two years of age or younger.
- Donor cartilage tissue may be obtained for example from a prenatal or neonatal donor no older than about one (1) week of age.
- Donor cartilage tissue may be obtained from a cadaver of an individual of juvenile age at time of death.
- Tissue pieces may be prepared from any donor or engineered source tissue by dividing the tissue into cuboids each having a volume less than 1 mm 3 , e.g cuboids of approximately 1 mm on each side. Dividing may be accomplished for example using a microcutter as known in the art. Multiple such tissue pieces may then be placed in culture, at an edge-to-edge distance of no more than 1 mm from at least one adjacent tissue piece.
- Cartilage defects that may be treated with a cartilage composition as described herein encompass any cartilage defect caused by injury or disease including any acute, partial, or full-thickness chondral injury, osteochondral injuries, and defects resulting from degenerative diseases or processes.
- the cartilage defect can be, for example and without limitation, the result of osteochondritis dissecans (OCD), osteoarthritis, rheumatoid arthritis, or osteonecrosis.
- kits including a tissue support as described herein, and a first container holding a plurality of the pre-expansion cartilage tissue pieces as also described herein.
- the kit may be suitably used for investigative or therapeutic purposes to prepare a cartilage composition as described herein from tissue pieces.
- the kit may further contain, for example, instructions for securing the plurality of cartilage tissue pieces to the tissue anchors on the support.
- the kit may further comprise a cartilage adhesive, which may be supplied for example in a separate container together with instructions for applying the cartilage adhesive to the surface defining the plurality of tissue anchors on the support.
- the cartilage adhesive may be applied to the surface defining the plurality of tissue anchors on the support.
- the cartilage adhesive may be applied for example to a plurality of predetermined locations on the surface of tissue anchors such that the cartilage adhesive is confined to the predetermined locations.
- a tissue culture system for preparing a cartilage composition for repair of a cartilage tissue defect may comprise a tissue support as described herein, and a plurality of cartilage tissue pieces, each cartilage tissue piece secured to a tissue anchor as also described herein.
- each cartilage tissue piece has an initial volume of less than 1 mm 3 , and may reach an expanded volume of at least 1 mm 3 , at least 1.5 mm 3 or at least 2 mm 3 .
- the cartilage tissue pieces in the system may comprise cartilage tissue pieces prepared from any donor or engineered source as described herein.
- the tissue culture medium may further any growth medium as described herein.
- Cartilage explants were obtained from calf and human juvenile donor tissue and prepared using a microcutter to a substantially cuboid shape of about 1.5 mm on a side.
- Four 1.5 mm diameter cartilage pieces were placed on a regular tissue culture plate at varying distances relative to each other: at 0, 0.5, 1.0, 2.0 and 3.0 mm and maintained in an incubator at 37° C., 5% CO 2 , in a growth medium as follows: all cultures were started with DMEM/F-12/FBS medium and switched to HL-1 serum-free medium after two weeks of culture.
- DMEM/F-12/FBS medium was prepared by supplementing DMEM/F12 medium with 10% (v/v) fetal bovine serum (FBS, Invitrogen) supplemented with ascorbate and L-glutamine as described above, 10,000 U/ml penicillin G, 10,000 U/ml streptomycin sulphate and 25 ⁇ g/ml amphotericin B (Invitrogen).
- FBS fetal bovine serum
- Serum free HL-1 medium was prepared from HL-1 serum-free medium (Lonza Walkersville, Inc., Walkersville, Md.) supplemented with 1:100 diluted HL-1 supplement (Lonza Walkersille, Inc.) supplemented with ascorbate and L-glutamine as described above 10,000 U/ml penicillin G, 10,000 U/ml streptomycin sulphate and 25 ⁇ g/ml amphotericin B.
- Spatial reorientation of an explant piece in culture resulted in the same effect on the former upper surface reoriented as the bottom surface.
- Spatial reorientation thus may provide a method of controlling/directing the orientation and shape of cartilage explant expansion.
- ECM extracellular matrix
- Calf cartilage explants were harvested from five different locations of knee joint: trochlea, trochlea groove, femoral condyle, central tibial plateau and peripheral tibial plateau.
- the pieces of calf cartilage from different sources were placed according to methods in Example 1. No significant difference was observed on cell migration, cartilage explant expansion and integration among the calf cartilage explants harvested from different locations of knee joint ( FIG. 18 ). Further evaluation was carried out with different sizes of calf cartilage explants. Calf cartilage explants of 1.5 mm, 2 mm, 3 mm and 4 mm in diameter were prepared and cultured according to methods as otherwise described in Example 1. No significant difference was observed on cell migration, cartilage explant expansion and integration among different sizes of calf cartilage explants ( FIG. 19 ).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present disclosure provides tissue supports and methods for preparing a cartilage composition for repairing cartilage defects, which is prepared by expanding and integrating small cartilage tissue pieces derived from donor or engineered tissue. The methods and supports described herein promote cell migration and integration of neighboring tissue pieces in culture to form the cartilage composition. Methods of cartilage repair using the cartilage composition are also described.
Description
- This application claims priority from U.S. Provisional Application No. 61/740,787, filed Dec. 21, 2012, the entire disclosure of which is herein incorporated by reference.
- The present disclosure relates generally to methods and compositions for expanding cartilage tissue explants in vitro, and in particular to a tissue support for promoting expansion and integration of cartilage tissue particles or pieces, and related methods.
- Injury and degeneration of cartilage tissue is a major clinical challenge for several reasons. In the epidemiological sense, arthritis and other degenerative joint diseases afflict a large proportion of aging populations, which are growing at high rates in most developed nations. In the clinical sense, healing of cartilage tissue is compromised by a lack of direct blood supply. When cartilage tissue alone is damaged, i.e., in the case of a chondral lesion, local chondrocytes can only achieve limited repair. A full-thickness articular cartilage injury, or osteochondral lesion, will elicit a complete inflammatory response, but results in poor tissue reformation. As a result, a surgical approach to repair and prevention of further injury can be the only viable option. Total artificial joints have been developed and used as replacements for many years with reasonable success. Total joint replacement is nevertheless costly, invasive, carries certain risks such as blood clots, blood loss and infection, and may not provide complete restoration of function. Additionally, although significant advances have been made over the last few decades in designing robust artificial joints, they do wear out. Total joint replacement in patients younger than about 60 must be carefully considered, given the risk of the artificial joint wearing out.
- Tissue engineering provides an alternative approach to joint repair. Engineered tissue, including cartilage tissue, can now be prepared in vitro and then implanted in an afflicted joint to replace damaged cartilage. The technical challenge has been how to engineer a tissue that has the biomechanical properties native to cartilage, and is also biocompatible. Various approaches have been tried with differing levels of success. One approach is to obtain cells from an acceptable donor source, and seed the cells onto some sort of scaffold that provides needed mechanical support, and then maintain the arrangement in culture with appropriate nutrients and growth factors with the expectation that the seeded cells will mature, or differentiate and mature, to the desired chondrocyte phenotype. While this approach generally holds promise, multiple technical obstacles remain, arising primarily from the difficulty in finding a suitably strong biocompatible material that also promotes chondrocyte differentiation, proliferation, phenotype retention and ability of chondrocytes to produce appropriate levels of cartilage-specific glycosoaminoglycans. Certain naturally-occurring and synthetic biopolymers have been investigated for such applications, with varying degrees of success.
- While significant progress has been made in successfully engineering small amounts of certain types of cartilage, many substantial barriers remain. In particular, engineered cartilage tissue that is sufficiently robust to apply to weight-bearing joints, rather than merely to cosmetic applications, remains a continuing objective. For true functionality within a joint, the resulting tissue must demonstrate the cellular characteristics and architecture of native cartilage, while commercial viability requires that the tissue be readily generated from the relatively small amounts of source tissue that is reasonably available. The field therefore continues to search for improved methods for promoting and sustaining cartilage tissue expansion from small initial amounts of donor tissue.
- In one aspect, the present disclosure provides a support for preparing a cartilage composition from a plurality of cartilage tissue pieces, the support comprising a biocompatible material having a surface defining a plurality of tissue anchors separated by a distance sufficient to secure the plurality of tissue pieces to the support at an inter-piece distance of 1 mm or less. Each tissue piece has a starting volume less than 1 mm3. The biocompatible material may comprise a solid material, such as for example at least one trabecular metal, or a semi-solid material such as for example a gel. The tissue anchors comprise a plurality of surface features such as pins, barbs, ridges, hooks, posts, recesses and/or apertures in the biocompatible material. The support may have a plurality of cartilage tissue pieces coupled to its surface, wherein each cartilage tissue piece is coupled to a tissue anchor on the support so that the tissue pieces are separated by an inter-piece distance of 1 mm or less. A cartilage adhesive is optionally applied to the surface defining the plurality of tissue anchors. The cartilage adhesive may be applied for example to a plurality of predetermined locations on the surface of tissue anchors, in such manner as to confine the cartilage adhesive to the predetermined locations.
- Also provided is a kit including any support as described herein, and a first container holding a plurality of cartilage tissue pieces. The kit may further comprise instructions for securing the plurality of cartilage tissue pieces to the tissue anchors on the support. The kit may further comprise a cartilage adhesive, which may be supplied for example in a separate container together with instructions for applying the cartilage adhesive to the surface defining the plurality of tissue anchors on the support. Alternatively, the cartilage adhesive may be applied to the surface defining the plurality of tissue anchors on the support. The cartilage adhesive may be applied for example to a plurality of predetermined locations on the surface of tissue anchors such that the cartilage adhesive is confined to the predetermined locations.
- In another aspect, the present disclosure provides a tissue culture system for preparing a cartilage composition for repair of a cartilage tissue defect, the tissue culture system including: a support including a biocompatible material having a surface defining a plurality of tissue anchors separated by a distance sufficient to secure a plurality of tissue pieces to the solid support at an inter-piece distance of 1 mm or less; and a plurality of cartilage tissue pieces, each cartilage tissue piece secured to a tissue anchor. In the tissue culture system, each cartilage tissue piece may have a volume of less than 1 mm3. The tissue culture system may comprise any support as described herein. The cartilage tissue pieces may comprise for example cartilage tissue obtained from a donor, which may be from a juvenile human donor. The cartilage tissue pieces may comprise engineered cartilage tissue.
- In another aspect, the present disclosure provides a method for preparing a cartilage composition for repair of a cartilage tissue defect, including: a) dividing cartilage tissue into a plurality of tissue pieces, each portion having an initial volume of less than 1 mm3, and b) maintaining the tissue pieces in a culture medium for a time and under conditions sufficient for each tissue piece to attain an expanded volume of at least 1 mm3, wherein the cell culture conditions comprise securing each tissue piece to a support, wherein the support includes a biocompatible material having a surface defining a plurality of tissue anchors separated by a distance sufficient to secure the plurality of tissue pieces to the solid support at an inter-piece distance of 1 mm or less. In the method, the support may be any of those as described herein. The cartilage tissue pieces may comprise for example cartilage tissue obtained from a donor, which may be from a juvenile human donor. The cartilage tissue pieces may comprise engineered cartilage tissue.
- In another aspect, the present disclosure provides a method for repair of a cartilage defect, including: a) dividing cartilage tissue into a plurality of tissue pieces, each portion having an initial volume of less than 1 mm3, and b) maintaining the tissue pieces in a culture medium for a time and under conditions sufficient for each tissue piece to attain an expanded volume of at least 1 mm3, wherein the cell culture conditions comprise securing each tissue piece to a support, wherein the support includes a biocompatible material having a surface defining a plurality of tissue anchors separated by a distance sufficient to secure the plurality of tissue pieces to the solid support at an inter-piece distance of 1 mm or less; c) removing the cartilage composition from the support; and d) implanting the cartilage composition into the cartilage defect. In the method, the support may be any of those as described herein. The cartilage tissue pieces may comprise for example cartilage tissue obtained from a donor, which may be from a juvenile human donor. The cartilage tissue pieces may comprise engineered cartilage tissue. The method may further comprise maintaining the tissue pieces in the culture medium for a time and under conditions sufficient for at least a first expanded tissue piece to attain an expanded volume sufficient for the first expanded tissue piece to contact at least a second expanded tissue piece. The culture conditions may comprise a culture medium including at least one additive from a class of agents selected from the group consisting of: chondrocytes, progenitor cells, stem cells, hormones, growth factors and cytokines.
- In another aspect, the present disclosure provides a method for repair of a cartilage defect, including: a) dividing cartilage tissue into a plurality of tissue pieces, each portion having an initial volume of less than 1 mm3; b) maintaining the tissue pieces in a culture medium for a time and under conditions sufficient for each tissue piece to attain an expanded volume of at least 1 mm3, wherein the cell culture conditions comprise securing each tissue piece to a support, wherein the support includes a biocompatible material having a surface defining a plurality of tissue anchors separated by a distance sufficient to secure the plurality of tissue pieces to the solid support at an inter-piece distance of 1 mm or less; and c) implanting and fixing the cartilage composition together with the solid support into the cartilage defect. In the method, the support may be any of those as described herein. The cartilage tissue pieces may comprise for example cartilage tissue obtained from a donor, which may be from a juvenile human donor. The cartilage tissue pieces may comprise engineered cartilage tissue. The method may further comprise maintaining the tissue pieces in the culture medium for a time and under conditions sufficient for at least a first expanded tissue piece to attain an expanded volume sufficient for the first expanded tissue piece to contact at least a second expanded tissue piece. The culture conditions may comprise a culture medium including at least one additive from a class of agents selected from the group consisting of: chondrocytes, progenitor cells, stem cells, hormones, growth factors and cytokines.
- In yet another aspect, the present disclosure provides a method for preparing a cartilage composition for repair of a cartilage tissue defect, including: a) dividing an amount of cartilage tissue into a plurality of tissue pieces defining a population, each portion having an initial volume of less than 1 mm3, and b) maintaining the tissue pieces in a culture medium for a time and under conditions sufficient for each tissue piece to expand so that the average volume of tissue pieces in the population is at least 1 mm3. In the method, the culture medium may comprise any of the additives as described herein. The cartilage tissue pieces may comprise for example cartilage tissue obtained from a donor, which may be from a juvenile human donor. The cartilage tissue pieces may comprise engineered cartilage tissue may be any of those as described herein. The method may further comprise maintaining the tissue pieces in the culture medium for a time and under conditions sufficient for each tissue piece to expand so that the average volume of tissue pieces in the population is at least 1.5 mm3. Alternatively, the tissue pieces may be maintained in the culture medium for a time and under conditions sufficient for each tissue piece to expand so that the average volume of tissue pieces in the population is at least 2.0 mm3. In the method, each tissue piece may be positioned on a culture surface at an inter-piece distance of 1 mm or less. The tissue piece may be secured to the culture surface at an inter-piece distance of 1 mm or less as it is positioned. The cartilage adhesive is optionally applied to an interface between each tissue piece and the culture surface.
- The cartilage adhesive may be applied for example to a plurality of predetermined locations on the surface, in such manner as to confine the cartilage adhesive to the predetermined locations. The method may further comprise maintaining the tissue pieces in the culture medium for a time and under conditions sufficient for at least a first expanded tissue piece to attain an expanded volume sufficient for the first expanded tissue piece to contact at least a second expanded tissue piece. The culture conditions may comprise a culture medium including at least one additive from a class of agents selected from the group consisting of: chondrocytes, progenitor cells, stem cells, hormones, growth factors and cytokines.
- In still another aspect, the present disclosure provides a cartilage composition for repair of a cartilage tissue defect, wherein the cartilage composition includes a plurality of expanded cartilage tissue pieces defining a population, wherein each tissue piece in the population is expanded from an initial volume of less than 1 mm3 to an expanded volume such that the population of expanded cartilage tissue pieces has an average expanded volume of at least 1 mm3. The average volume of expanded cartilage tissue pieces in the population is for example at least 1.5 mm3. Alternatively, the average volume of expanded cartilage tissue pieces in the population is at least 2.0 mm3. In the cartilage composition, each expanded tissue piece in the population contacts at least one other expanded tissue piece. The cartilage tissue pieces may comprise for example cartilage tissue obtained from a donor, which may be from a juvenile human donor. The cartilage composition may further comprise a culture medium including at least one additive from a class of agents selected from the group consisting of: chondrocytes, progenitor cells, stem cells, hormones, growth factors and cytokines. In the provided cartilage composition, the expanded cartilage tissue pieces are obtained by a) dividing an initial amount of cartilage tissue into a plurality of cartilage tissue pieces defining a population, each portion having an initial volume of less than 1 mm3, and b) and maintaining the cartilage tissue pieces in a culture medium for a time and under conditions sufficient for each tissue piece to expand so that the average volume of tissue pieces in the population is at least 1 mm3. For the cartilage composition, the step of obtaining the expanded tissue pieces further comprise before step (b), the step of positioning each tissue piece on a culture surface at an inter-piece distance of 1 mm or less. As a result, the present invention also provides use of the cartilage composition as disclosed herein to repair a cartilage defect in a subject in need thereof.
- In yet another aspect, the present disclosure provides a method for repair of a cartilage defect, including: implanting and fixing into the cartilage defect a cartilage composition including a plurality of expanded cartilage tissue pieces defining a population, wherein each tissue piece in the population was expanded from an initial volume of less than 1 mm3 to an expanded volume such that the population of expanded cartilage tissue pieces has an average expanded volume of at least 1 mm3. In the method, the average volume of expanded cartilage tissue pieces in the population is at least 1.5 mm3. Alternatively, the average volume of expanded cartilage tissue pieces in the population is at least 2.0 mm3. In the population of expanded cartilage tissue pieces, at least a first expanded tissue piece contacts at least a second expanded tissue piece. In one example, each expanded cartilage tissue piece in the population contacts at least one other expanded tissue piece. The cartilage tissue pieces may comprise for example cartilage tissue obtained from a donor, which may be from a juvenile human donor. The cartilage tissue pieces may comprise engineered cartilage tissue may be any of those as described herein. The cartilage composition in the method may further comprise a culture medium including at least one additive from a class of agents selected from the group consisting of: chondrocytes, progenitor cells, stem cells, hormones, growth factors and cytokines.
-
FIG. 1 is a perspective, top view of a first exemplary tissue support with enlarged view of tissue anchors in form of small pins projecting from the upper surface of the tissue support. -
FIG. 2 is a cross-sectional view of a second exemplary tissue support, showing tissue anchors in the form of recessions on the upper surface of the tissue support. -
FIG. 3 is a cross-sectional view of the first exemplary tissue support ofFIG. 1 , showing small tissue pieces placed on the pins. -
FIG. 4 is a cross-sectional view of the second exemplary tissue support ofFIG. 2 , showing small tissue pieces placed in the recessions. -
FIG. 5 is a series of photomicrographs showing expansion of calf and human juvenile cartilage explants in culture. -
FIG. 6 is a series of photomicrographs showing non-uniform expansion of cultured cartilage explants. -
FIG. 7 is a photomicrograph showing the structural interactions observed between cultured calf cartilage pieces at day 5 of culture (20×), when maintained at an inter-piece distance of 1 mm. -
FIG. 8 is a photomicrograph showing the structural interactions observed between cultured human juvenile cartilage pieces at day 5 of culture (5×), when maintained at an inter-piece distance of 1 mm. -
FIG. 9 is a photomicrograph showing results obtained with calf cartilage explants that were cultured with different inter-piece distances, showing structural integration of two neighboring pieces only when they the inter-piece distance was no greater than 1 mm. -
FIG. 10 is a photomicrograph showing results obtained with calf cartilage explants during an initial culture phase in which inter-piece interactions including simultaneous cell migration into the inter-piece area and production of ECM. Newly formed ECM along with the cells embedded inside can be seen as a bridge between the two neighboring pieces which “glues” the cells together. -
FIG. 11 is a series of photomicrographs showing the formation of inter-piece interactions of human juvenile cartilage explants. The cells migrated into the inter-piece area and produce ECM simultaneously. The newly formed ECM along, with the embedded cells, can be seen as a bridge between the two pieces which “glues” the cells together. Inter-piece interactions enclosed by the red circle in A (5×) are shown in B (20×). Inter-piece interactions enclosed by the red circles in C (5×) are shown in D and E (20×). -
FIG. 12 is a pair of photomicrographs of calf cartilage explants showing structural inter-piece interactions over time, which became denser and stringer over time. The newly formed interactions contain both cells and ECM. A: day 24 of culture (20×), B:day 38 of culture (20×). -
FIG. 13 is a series of photomicrographs of human juvenile cartilage explants showing the inter-piece interactions over time, which became denser and stronger over time. The newly formed interactions contain both cells and ECM. A: day 26 of culture (10×), B: day 64 of culture (10×). C: the newly formed inter-piece interactions on day 64 of culture (20×). -
FIG. 14 is a pair of photomicrographs of calf cartilage explants showing structural inter-piece interactions over time, which became thicker and wider over time. Inter-piece interactions are highlighted by the red circle. A: day 42 of culture (5×), B:day 120 of culture (5×). -
FIG. 15 is a series of photomicrographs of histologically stained cultured calf cartilage explants at 10 weeks of culture, in which newly formed inter-piece interaction areas are enclosed by the red circles. A: the two calf cartilage pieces at 10 weeks of culture before histology staining B: and C: Masson's trichrome staining, D: and E: H:-E: staining, F: Alcian blue staining and G: Safranin O Staining C: and E: show the cell migration out of the edges of the original calf cartilage pieces. -
FIG. 16 is a pair of photomicrographs showing cultured cartilage pieces positioned at an inter-piece distance of greater than 1 mm were mainly surrounded by the migrated cells. A: calf cartilage explants (10×), B: human juvenile cartilage explants (10×). -
FIG. 17 is a pair of photomicrographs of results after 10 weeks of culture, showing cells that migrated out of human juvenile cartilage explant proliferated and accumulated next to the original tissue pieces, where they piled up as multiple layers and reached approximately the same height of the cartilage pieces. A: 5×, B: 10×. -
FIG. 18 is a series of photomicrographs showing effects of cartilage harvesting locations: A: trochlea, B: trochlea groove, C: femoral condyle, D: central tibial plateau and E: peripheral tibial plateau. Pictures were taken onday 35 of culture. -
FIG. 19 is a photomicrograph showing results obtained with calf cartilage explants of different sizes. -
FIG. 20 is a series of photomicrographs showing migrated cells from calf cartilage explants having different phenotypes, on TC and ULA plates. A: the bottom layers of cell attached to the bottom area of TC plates onday 35 of culture (10×). B: The initial formation of cell cluster from individual cells on ULA plates onday 35 of culture (10×). C: Multiple layers of cells formed on the bottom of TC plates onday 120 of culture. The top layer of cells showed un-stretched round shape (10×). D: More and bigger cell clusters were formed on ULA plates onday 120 of culture, the majority of cells inside the cluster showed round shape (20×). - The present disclosure is based in part on the surprising discovery that small cartilage tissue pieces, when maintained in vitro under culture conditions, will expand and structurally integrate with neighboring tissue pieces when maintained at an inter-piece distance of 1 mm or less than 1 mm. By “inter-piece distance” is meant that distance from an outside surface of one tissue piece to the closest outside surface of a second tissue piece adjacent to the first tissue piece. Exemplary tissue pieces have a volume of less than about 1 mm3, and may be of many possible shapes, e.g., cubes, cylinders, ovoids, and the like, which may be produced according to the method of preparing the pieces from a tissue source. An outside surface of a tissue piece may therefore be substantially linear or arcuate, depending on the shape of the tissue piece. For example, tissue pieces may be substantially cuboid, with substantially linear outer surfaces, and have a volume of less than about 1 mm3, e.g., dimensions of less than approximately 1 mm on each side. It has now been found that two neighboring cartilage pieces when placed no more than 1 mm apart, form new tissue through the activity of cells that migrate from each piece and interact to form a structurally integrated larger piece of tissue over time. In marked and surprising contrast, neighboring such tissue pieces that are placed more than 1 mm apart do not expand and integrate in the same way. Importantly, it has further now been demonstrated that when placed and maintained while in culture as described, cells from the initial tissue pieces will migrate into the area between two cartilage pieces and produce extracellular matrix (ECM) simultaneously. The newly formed ECM, along with cells embedded therein, forms new inter-piece tissue that binds neighboring pieces together. Additionally, more cells migrate over time onto the inter-piece tissue, and cells already embedded inside the ECM also continue to proliferate. As a result, the ECM becomes denser, and the volume of the inter-piece tissue, which consists of multiple layers of ECM and cells embedded therein, increases. The increase in tissue volume is reflected in an increase in height, width and/or length of the inter-piece tissue, which also becomes structurally integrated with the neighboring tissue pieces. Particularly surprising is the finding that the thus newly formed inter-piece tissue exhibits structure that is comparable to that of the original cartilage tissue, based on gross and histological evaluation. The expanded tissue thus provides a new source for a cartilage composition that can be used for cartilage repair.
- Section headings as used in this section and the entire disclosure herein are not intended to be limiting. Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
- As used herein, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. For the recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range 6-9, the
numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 and 7.0 are explicitly contemplated. - As used herein, the term “about” refers to approximately a +/−10% variation from the stated value. It is to be understood that such a variation is always included in any given value provided herein, whether or not it is specifically referred to.
- As used herein, the term “biocompatible material” or biomaterial refers to a synthetic or natural material that can be used to replace part of a living system or to function when in close contact with living tissue.
- As used herein, the term “cartilage” refers to an avascular tissue, having chondrocytes encapsulated within an extracellular matrix. As used herein, cartilage tissue may be donor cartilage tissue or engineered cartilage tissue. “Cartilage,” as used herein, encompasses articular cartilage, hyaline cartilage, neocartilage (Adkisson, H. D. et al., Clin. Orthop. 391S: S280-S294, 2001; and U.S. Pat. Nos. 6,235,316 and 6,645,316), devitalized cartilage, auricular cartilage, cartilage including genetically modified chondrocytes, cartilage from an autogenous source, cartilage from an allogenic source, cartilage from a xenogeneic source, juvenile cartilage, or a combination thereof. In some configurations, cartilage can also comprise chondrocytes differentiated from precursor cells such as mesenchymal stem cells.
- As used herein, the term “cartilage adhesive” refers to molecular species or mixtures of species which promote adhesion of cartilage tissue or chondrocytes of the cartilage tissue to a surface, by acting as a binding agent (e.g., a glue) and/or by promoting adhesion-forming activity of cells. A cartilage adhesive can be used as a binding agent (e.g., a glue) at the interface between cartilage or chondrocytes thereof and a surface.
- The term “cartilage defect” refers to a structural and/or biological imperfection in cartilage tissue such as but not limited to a break, tear, void or other disintegration of the tissue, which is caused by a disease, injury or condition and which can benefit from cartilage repair, replacement, or augmentation, such as, in non-limiting example, athletic injury, traumatic injury, congenital disorders, osteoarthritis and joint degeneration from aging.
- As used herein, the term “chondrogenic cell” as used herein refers to chondrogenic progenitor cells (CPCs), the further differentiation of which results in chondrocytes. Chondrogenic cells can come from a variety of sources. Generally, the chondrogenic cells can be isolated from an articular cartilage or a fibrocartilage. Chondrogenic cells from a fibrocartilage can be obtained from costal, nasal, auricular, tracheal, epiglottic, thyroid, arytenoid and cricoid cartilages. Alternatively, cells from fibrocartilage can be obtained from tendon, ligament, meniscus and intervertebral disc. Depending on the context, chondrogenic cells may refer to partially differentiated progenitor cells destined to be chondrocytes or chondrogenic stem cells that are more primitive. The chondrogenic stem cells can be derived from a tissue such as placenta, umbilical cord, bone marrow, skin, muscle, fat, periosteum, and perichondrium.
- The term “subject” as used herein refers to a mammal, which may be a human or a non-human mammal such as but not limited to a horse, a dog, a cat, a non-human primate such as a monkey or ape, a rabbit, a rat, a mouse, or a pig.
- The term “trabecular metal,” as used herein, encompasses any biocompatible metal or metal composite having interconnecting pores and at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 85% porosity by volume. Exemplary such metals have pores of about 200 μm-700 μm in diameter, and preferably 400 μm-600 μm in diameter. Descriptions of trabecular metal, as well as various methods of making trabecular metal of various pore sizes are known in the art. An exemplary such material is a tantalum composite sold as Trabecular Metal® by Zimmer, Inc.
- In one aspect, the present disclosure provides a support for preparing a cartilage composition from a plurality of cartilage tissue pieces, the support including a biocompatible material having a surface defining a plurality of tissue anchors separated by a distance sufficient to secure the plurality of tissue pieces to the support at an inter-piece distance of 1 mm or less. Tissue pieces of varying initial volumes may be used. A tissue piece may for example have a starting volume of about 1 mm3, or less than about 1 mm3, or more than about 1 mm3. For example, a population of tissue pieces having an initial average volume of less than 1 mm3, maintained at an inter-portion distance of 1 mm or less, can expand as described herein to attain an average volume of at least 1.5 mm3 or 2.0 mm3 and thereby integrate with surrounding pieces. It should nevertheless be appreciated that if the tissue pieces are cultured under more favorable expansion conditions, for example by the addition of growth factors to the culture system, the tissue pieces may attain a greater volume within a given period of time, and thereby integrate two neighboring pieces that are maintained at a distance of more than 1 mm apart.
- Similarly, with respect to the initial volume of the tissue pieces, although an exemplary tissue piece size is about 1 mm3, or less than about 1 mm3, the initial tissue size (volume) could be larger than about 1 mm3 and still suitably expand as described herein.
- Tissue pieces may vary in shape and may be for example substantially spherioid, cuboid, cylindrical, or ovoid. It should be understood that the shape of the tissue pieces will depend in part on the method used to prepare tissue pieces from the donor tissue. A non-limiting exemplary tissue piece is substantially cuboid and has a starting volume less than about 1 mm3, e.g., dimensions of less than approximately 1 mm on each side. The biocompatible material may comprise a solid material, such as for example at least one trabecular metal, or a semi-solid material such as for example a gel.
- The tissue anchors comprise a plurality of surface features such as pins, barbs, ridges, hooks, posts, recesses and/or apertures in the biocompatible material. The support may have a plurality of cartilage tissue pieces coupled to its surface, wherein each cartilage tissue piece is coupled to a tissue anchor on the support so that the tissue pieces are separated by an inter-piece distance of 1 mm or less. A cartilage adhesive is optionally applied to the surface defining the plurality of tissue anchors. The cartilage adhesive may be applied for example to a plurality of predetermined locations on the surface of tissue anchors, in such manner as to confine the cartilage adhesive to the predetermined locations. Alternatively, the tissue anchors may be provided solely as adhesive spots in predetermined locations on an otherwise featureless surface of the support.
- Accordingly, the present disclosure encompasses tissue supports for maintaining tissue pieces at an inter-piece distance of 1 mm or less. As shown in
FIG. 1 for example, atissue support 100 is generally made of abiocompatible material 102 having asurface 104 defining multiple tissue anchors 106 for securing tissue pieces to support 100. The tissue anchors may take the form of any of a number of suitable surface projections fromsurface 104. As shown inFIG. 1 , for example, each tissue anchor is apin 108. Other projecting forms suitable for securing tissue pieces can be used, such as but not limited to barbs, ridges, hooks, or straight or curved posts. Alternatively, the tissue anchors may generally take the form of depressions or recesses 110 insurface 104, as shown inFIG. 2 , or they may consist of apertures throughbiocompatible material 102. Such depressions, recesses or apertures throughbiocompatible material 102 may for example be configured with a shape and/or dimensions approximately matched to the shape and/or dimensions of the tissue pieces. For example, apertures for receiving substantially spherical tissue pieces may be configured as round holes throughbiocompatible material 102, having a diameter approximating the average diameter of the tissue pieces. Alternatively, the tissue anchors may consist solely of defined adhesive locations (not shown) onsurface 104, wherein the adhesive locations are created by applying a cartilage adhesive to defined locations, e.g., as “dots” or “spots” of adhesive, onsurface 104, which is otherwise free of physical anchors such as projecting anchors, or depressions or apertures. - The multiple tissue anchors are distributed substantially uniformly across
surface 104 in any configuration such that each anchor is positioned at a maximum distance of about 1 mm to about 2 mm from at least one neighboring tissue anchor. The distribution of tissue anchors acrosssurface 104 may be according to any regular or irregular pattern, provided that each anchor is no more than a maximum distance of about 1 mm to about 2 mm from at least one neighboring anchor, so that each tissue piece is able to expand and integrate with at least one neighboring piece. It will be appreciated that any distribution pattern that maximizes packing of the initial tissue pieces acrosssurface 104 within the specified maximum distance, and thus any regular, geometric distribution pattern of the tissue anchors, will be preferred. - It should further be appreciated that the tissue anchor dimensions may suitably vary depending on the size and/or density of the tissue piece(s), and on the shape of the anchor. Tissue anchors should be sized and shaped such that the act of applying and securing a tissue piece to an anchor will not obliterate most or all of the tissue piece. For example, a tissue piece having a generally cuboid shape of about 1 mm on a side, or a thinner tissue piece of about 1 mm in length and 1 mm in width, may be anchored to the support surface using an anchor configured as a straight pin, with a largest diameter of about 50-500 microns. Anchors for tissue pieces larger than about 1 mm on a side may be appropriately sized to have a larger diameter or other cross-sectional area.
- It should further be appreciated that the tissue support shape may be varied to approximate the shape of an anatomical target, such that the tissue generated on the support in vitro will approximate the target anatomical shape. For example, a support may have an arcuate shape such that the resulting tissue is appropriately shaped to be implanted at the acetabulum, head of the femur or other curved anatomic surface. A support may have a generally pyramidal shape for implantation at a talar dome lesion or fracture. Other shapes suitably adapted for other anatomical targets are also contemplated.
- Each tissue piece is secured to surface 104 by applying, e.g. manually, each piece at its approximate center onto a tissue anchor, as shown in
FIG. 3 andFIG. 4 . It should therefore be appreciated that with initial tissue particles having approximate dimensions of 1 mm on each side, using tissue anchors that are separated by a distance of about 1 mm will provide an inter-piece distance of about 0.0 mm, e.g., the initial tissue pieces are in contact or very close to contacting neighboring piece(s). Tissue anchors that are separated by a distance of about 2 mm will provide an inter-piece distance of about 1.0 mm, i.e., a distance at which the initial tissue pieces are at or close to the maximum inter-piece distance, according to the findings and methods disclosed herein. Each piece is secured in position on an anchor by piercing, lancing or hooking the piece onto a projecting anchor onsurface 104, or by depositing (e.g., by manually pressing) each piece at least partially into an anchor that is a depression, recess or anchor insurface 104. To use a tissue support that has only adhesive locations as anchors, the cartilage adhesive is applied, e.g. by manually “dotting” or “spotting” the cartilage adhesive ontosurface 104 in selected locations, applying a population of tissue pieces to surface 104, waiting for a period of time sufficient for a subset of the tissue pieces to bind or adhere to the selected locations, and then removing all unbound or non-adhered tissue pieces, e.g. by washing or rinsing the unbound pieces way. - A cartilage adhesive is optionally used to further secure each tissue piece in position on the tissue support, for example by the applying cartilage adhesive to an interface between each tissue piece and a tissue support surface. Depending on the configuration of the tissue support, e.g. the type of anchors being used, a cartilage adhesive may be applied to tissue anchor surfaces, or to inter-anchor regions of the tissue support, or to both. Use of a cartilage adhesive may be desired for example when the support has anchors that do not otherwise secure the tissue pieces to the support through physical means such as piercing or hooking, e.g. depressions or apertures. For avoidance of doubt, cartilage adhesive may be used with any of the anchor forms described herein. A cartilage adhesive may be any biologically compatible composition capable of adhering to both
biocompatible material 102 and the tissue pieces. For example, a cartilage adhesive may be, but is not limited to, a fibrin-based adhesive, a collagen-based adhesive or a combination thereof. A cartilage adhesive can comprise for example tissue trans-glutaminase, hyaluronic acid, collagen type I, collagen type II, a chemically cross-linked collagen, fibrin, albumin, gelatin, elastin, silk, demineralized bone matrix, polyethylene oxide, polyethylene glycol, polyvinyl alcohol, polypropylene fumarate or a combination thereof as described elsewhere, or a hydrogel. (See, e.g., Jurgensen et al., J. Bone and Joint Surg. 79A: 185-193, 1997; U.S. Pat. No. 6,893,466 to Trieu; U.S. Pat. No. 6,835,277 to Goldberg et al). In various aspects, a vertebrate-derived component of a cartilage adhesive, such as tissue trans-glutaminase, hyaluronic acid, collagen type I, collagen type II, fibrin, albumin, gelatin, or elastin, or demineralized bone matrix, can be autologous, allogeneic, or xenogeneic to a mammalian recipient of an implant, such as a human patient in need of treatment. Furthermore, a protein or polypeptide component of a cartilage adhesive such as tissue trans-glutaminase, hyaluronic acid, collagen type I, collagen type II, fibrin, albumin, gelatin, or elastin, can be obtained from a naturally-occurring source such as an animal or human donor, or can be produced using molecular biological methods well known to skilled artisans, such as expression of a gene or cDNA encoding the protein in transformed or transfected cells (see, e.g., Sambrook, J., et al., Molecular Cloning: A Laboratory Manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001). A cartilage adhesive may also comprise one or more cell-attachment factors, such as collagen I or collagen IV, fibronectin, laminin, or poly-lysine, or another commercially available cell attachment factor, inasmuch as chondrocytes are exposed at a surface of a tissue piece. - The cartilage adhesive may be applied for example to a plurality of predetermined locations on the surface of tissue anchors, in such manner as to confine the cartilage adhesive to the predetermined locations. The cartilage adhesive may be applied for example directly to any projecting anchor such as a pin, hook or barb, to complement the physical coupling of each tissue piece to such an anchor. Alternatively, the cartilage adhesive may be applied to the surface of the support surrounding an anchor that is a depression, recess or aperture through the support, or to the depression or recess itself, or to the internal walls of an aperture, or any combination thereof.
-
Biocompatible material 102 may comprise any of a number of materials suitable for use in tissue culture and may comprise a material or materials that enhance cell migration, cell attachment and the formation of extracellular matrix of the cells. Such materials include for example a metal, either a single metal or a combination of metals. Accordingly, titanium, cobalt, chromium, platinum, iridium, niobium or tantalum may be used, or any alloy thereof, and also stainless steel. Any metal may be a trabecular metal. Ceramics may be used, such as but not limited to calcium hydroxylapatite (dense or porous), bioactive glass (e.g., Bioglass®, Ceravital®), bioactive glass-ceramics (A/W glass-ceramic such as Cerabone®, or dense or porous hydroxyapatite), and workable glass-ceramics and phosphates glasses such as Bioverit® I, II and III. Alternatively, suitable biocompatible materials also include biopolymers such as poly-lactic acid (PLA), poly-glycolic acid (PGA), Dacron, collagen, PET (poly-ethylene terephthalate), poly-carbonate, poly-tetrafluoroethylene, and co-polymers of PLA and PGA. Alternatively, the biocompatible material may comprise a semi-solid material such as for example a gel, such as a hydrogel, or a wax. A biocompatible material may include any combination of any of the above, for example but not limited to a layered configuration with one or more core layers of certain material(s) covered by a surface layer of a different material. Alternatively, protein layers may be attached to the surface of any material to promote cell attachment. - It will be appreciated that the tissue support, though illustrated in the accompanying drawings as a substantially flat surface with tissue anchors projecting therefrom, may alternatively be configured in any shape such as one specially adapted for implantation into a particular defect, provided only that the shape includes at least one surface capable of bearing multiple tissue anchors. It should be further recognized that certain biocompatible materials suitable as the support material and also having some amount of flexibility, such as gels, waxes and any composite material containing a gel or wax, may be especially suitable for in vitro applications.
- Methods for manufacturing a tissue support as described will depend on the material(s) selected and desired shape of the support, and are well known in the art. Precision manufacturing services are provided by many contract manufacturing organizations specializing in the manufacture of medical devices which provide manufacturing services including casting, extrusion, molding, and precision machining including milling and micromachining techniques such as microfinishing (deburring and polishing).
- The present disclosure encompasses methods for preparing a cartilage composition by dividing cartilage tissue into a plurality of tissue pieces, each having an initial volume of less than 1 mm3, and maintaining the tissue pieces in a culture medium for a time and under conditions sufficient for each tissue piece to attain an expanded volume of at least 1 mm3 or more, e.g. at least 1.5 mm3 or at least 2 mm3. The present disclosure also provides a method for repair of a cartilage defect by implanting and fixing into the cartilage defect a cartilage composition including a plurality of expanded cartilage tissue pieces having an average expanded volume of at least 1 mm3, at least 1.5 mm3 or at least 2 mm3.
- In the methods, sufficient time for each tissue piece to attain an expanded volume of at least 1 mm3 or more is at least about 4 days, and can be for example as long as 14 days. While each piece may not actually attain an expanded volume of at least 1 mm3 or more in the time period, it is contemplated that a minimum time of about 4 days under appropriate culture conditions is sufficient for at least 10%, 20%, 30%, 40%, 50%, 60, 70%, 80%, 90% or 100% of the tissue pieces to attain an expanded volume of at least 1 mm3 or more. It should be understood that due to variation among pieces including differences in the microclimate, not all pieces will expand and integrate with neighboring pieces at the same rate. Longer periods of time will result in more pieces attaining a minimum expanded volume, and also more pieces that attain an expanded volume greater the minimum expanded volume.
- Tissue culture conditions suitable for expanding and maintaining cartilage tissue as described herein are well known in the art. Generally, tissue including actively dividing cells is grown and maintained at an appropriate temperature which for mammalian cells, is at or about 37° C., and using a gas mixture of 5% CO2. To help accurately control conditions, tissue may be maintained for example in an incubator, in a growth medium. It will be appreciated that the formulation for a suitable growth medium may be varied along several factors: pH, glucose concentration, number and amount of growth factors, and presence of other nutrients. Growth factors derived from a number of sources may be used, including whole animal serum such as bovine calf serum. A suitable growth medium is, in non-limiting example, DMEM/F12 medium supplemented with fetal bovine serum (FBS). Alternatively, a serum-free medium or a chemically defined medium may be used, which may be supplemented with ascorbate and/or glutamine. A suitable such growth medium is, in non-limiting example, HL-1 serum-free medium (Lonza Walkersville, Inc., Walkersville, Md.) supplemented with at least about 2 mM or more of glutamine, and about 50 to about 100 μg/ml ascorbate. A culture medium may include at least one additive from a class of agents selected from the group consisting of: chondrocytes, progenitor cells, stem cells, hormones, growth factors and cytokines, or any composition containing such an additive or additives such as platelet rich plasma (PRP). Progenitor cells and stem cells include for example cartilage progenitor cells or bone marrow cells. Growth factors and cytokines may be any from among the many known such agents, including but not limited to ECGF (Endothelial Cell Growth Factor), VEGF 168, VEGF 145, VEGF 121, aFGF (Fibroblast Growth Factor, acidic), bFGF (Fibroblast Growth Factor, basic), EGF (epidermal growth factor), PDGF (platelet derived growth factor), FGF-10, FGF-4, FGF-5, FGF-6, FGF-8b, FGF-9, IGF (insulin-like growth factor), KGF (Keratinocyte Growth Factor), TGF-β (transforming growth factor β), collagen, hypothemycin, interleukin-8 (IL-8), and IL-13. The hormones may be chosen from hydrocortisone, insulin, triiodothyronine, thyroxine, Retinyl acetate, Activin A, (2-Hydroxypropyl)-β-cyclodextrin, Methyl-β-cyclodextrin, and Hydrocortisone 21-hemisuccinate.
- The cell culture conditions may include for example maintaining the tissue pieces at an inter-piece distance of 1 mm or less. This may be accomplished for example by securing each tissue piece to a tissue support as described herein. In use, as shown in
FIGS. 3 and 4 ,tissue support 100 has a plurality of cartilage tissue pieces coupled to its surface via the tissue anchors onsupport 100, such that the tissue pieces are separated by an inter-piece distance of 1 mm or less. It should be understood however that other means for maintaining the inter-piece distance are encompassed by the present disclosure. - The methods further encompass methods for repairing a cartilage defect, for example in a subject. The cartilage expansion methods as described herein may be applied for example to methods to prepare a cartilage composition in vitro for subsequent implantation into a subject for repair of a cartilage tissue defect in the subject. Alternatively, the approach can be adapted to methods to generate a cartilage composition in vivo in the subject.
- A method for repair of a cartilage defect may include for example producing in vitro a cartilage composition on a support, from cartilage pieces each having an initial volume of less than 1 mm3 as described herein, by expanding the initial cartilage pieces in vitro to an expanded volume of at least 1 mm3, followed by removing the resulting cartilage composition from the support, and then implanting and fixing the cartilage composition into the cartilage defect. Alternatively, a method for repair of a cartilage defect may include producing in vitro a cartilage composition on a support as described herein, and then implanting the cartilage composition together with the solid support into the cartilage defect, and closing the surgical opening such that the tissue pieces expand in vivo to an expanded volume of at least 1 mm3 or more. It will be appreciated that the latter alternative favors the use of a tissue support that is either prepared from a flexible material or materials, or is configured in a shape that fits closely with the defect being repaired.
- Alternatively, a method for preparing a cartilage composition for repair of a cartilage tissue defect may involve a population of tissue pieces, wherein a) an amount of cartilage tissue is divided into a plurality of tissue pieces defining a population, each portion having an initial volume of less than 1 mm3, and b) the tissue pieces are maintained in a culture medium for a time and under conditions sufficient for each tissue piece to expand so that the average volume of tissue pieces in the population is at least 1 mm3. The tissue pieces may be maintained for a time and under conditions sufficient for each tissue piece to expand such that the average volume of tissue pieces in the population is greater than 1 mm3, for example at least 1.5 mm3, or at least 2.0 mm3. This approach may include positioning each tissue piece on a culture surface, such as a tissue support as described herein, at an inter-piece distance of 1 mm or less before the expansion step (b). Each such tissue piece may be secured to such a support by means of an anchor or a cartilage adhesive, both as described herein, or a combination thereof.
- In any of the methods, the tissue pieces, which may be a population of tissue pieces, may be maintained for a time and under conditions sufficient for at least one, or more, of the tissue pieces to expand and thereby attain an expanded volume that is sufficient for the tissue piece(s) to contact at least one neighboring tissue piece that has also expanded. In an exemplary method, a starting population of tissue pieces is maintained for a time and under conditions sufficient for a simple majority if tissue pieces in the population, or for as many as all tissue pieces in the population, or for any number of tissue pieces in between a simple majority and the entire population, to expand and thereby attain an expanded volume that is sufficient for the tissue piece(s) to contact at least one neighboring tissue.
- By repair is meant a surgical repair such as an open surgical procedure (arthrotomy) or an arthroscopic procedure by which the in vitro prepared cartilage composition is implanted into the defect, with or without the tissue support. The cartilage composition, or cartilage composition together with the support, may be fixed in the defect using a mechanical fastener such as a staple, screw, pin or the like, or a tissue adhesive such as for example any adhesive described elsewhere herein.
- In any of the methods, cartilage tissue pieces or pieces may, without limitation, be prepared from donor or engineered cartilage tissue such as neocartilage, or a combination thereof. Source tissue may be allogeneic to, autologous to, and/or xenogeneic to a mammalian recipient such as a human patient. Cartilage tissue pieces may comprise for example, hyaline cartilage or any tissue including chondrocytes having the potential to generate hyaline cartilage, but not necessarily organized into histologically recognizable cartilage. Such tissue includes, for example, articular joint cartilage including knee joint and hip joint cartilage, tracheal cartilage, laryngeal cartilage, costal cartilage, epiphyseal plate cartilage, and any combination thereof. It will be understood that the methods and devices can be utilized to produce cartilage composition of various sources to meet the needs for treating cartilage defects of any origin. Donor cartilage tissue may be obtained from a live or a deceased donor. Donor cartilage tissue may be obtained for example from a juvenile donor, for example a donor less than fifteen years of age, preferably fourteen years of age or younger, and more preferably two years of age or younger. Donor cartilage tissue may be obtained for example from a prenatal or neonatal donor no older than about one (1) week of age. Donor cartilage tissue may be obtained from a cadaver of an individual of juvenile age at time of death.
- Tissue pieces may be prepared from any donor or engineered source tissue by dividing the tissue into cuboids each having a volume less than 1 mm3, e.g cuboids of approximately 1 mm on each side. Dividing may be accomplished for example using a microcutter as known in the art. Multiple such tissue pieces may then be placed in culture, at an edge-to-edge distance of no more than 1 mm from at least one adjacent tissue piece.
- Cartilage defects that may be treated with a cartilage composition as described herein encompass any cartilage defect caused by injury or disease including any acute, partial, or full-thickness chondral injury, osteochondral injuries, and defects resulting from degenerative diseases or processes. The cartilage defect can be, for example and without limitation, the result of osteochondritis dissecans (OCD), osteoarthritis, rheumatoid arthritis, or osteonecrosis.
- Also provided is a kit including a tissue support as described herein, and a first container holding a plurality of the pre-expansion cartilage tissue pieces as also described herein. The kit may be suitably used for investigative or therapeutic purposes to prepare a cartilage composition as described herein from tissue pieces. The kit may further contain, for example, instructions for securing the plurality of cartilage tissue pieces to the tissue anchors on the support. The kit may further comprise a cartilage adhesive, which may be supplied for example in a separate container together with instructions for applying the cartilage adhesive to the surface defining the plurality of tissue anchors on the support. Alternatively, the cartilage adhesive may be applied to the surface defining the plurality of tissue anchors on the support. The cartilage adhesive may be applied for example to a plurality of predetermined locations on the surface of tissue anchors such that the cartilage adhesive is confined to the predetermined locations.
- A tissue culture system for preparing a cartilage composition for repair of a cartilage tissue defect may comprise a tissue support as described herein, and a plurality of cartilage tissue pieces, each cartilage tissue piece secured to a tissue anchor as also described herein. In the tissue culture system, each cartilage tissue piece has an initial volume of less than 1 mm3, and may reach an expanded volume of at least 1 mm3, at least 1.5 mm3 or at least 2 mm3. The cartilage tissue pieces in the system may comprise cartilage tissue pieces prepared from any donor or engineered source as described herein. The tissue culture medium may further any growth medium as described herein.
- Various embodiments of the present teachings can be illustrated by the following non-limiting examples. The following examples are illustrative, and are not intended to limit the scope of the claims.
- Cartilage explants were obtained from calf and human juvenile donor tissue and prepared using a microcutter to a substantially cuboid shape of about 1.5 mm on a side. Four 1.5 mm diameter cartilage pieces were placed on a regular tissue culture plate at varying distances relative to each other: at 0, 0.5, 1.0, 2.0 and 3.0 mm and maintained in an incubator at 37° C., 5% CO2, in a growth medium as follows: all cultures were started with DMEM/F-12/FBS medium and switched to HL-1 serum-free medium after two weeks of culture. DMEM/F-12/FBS medium was prepared by supplementing DMEM/F12 medium with 10% (v/v) fetal bovine serum (FBS, Invitrogen) supplemented with ascorbate and L-glutamine as described above, 10,000 U/ml penicillin G, 10,000 U/ml streptomycin sulphate and 25 μg/ml amphotericin B (Invitrogen). Serum free HL-1 medium was prepared from HL-1 serum-free medium (Lonza Walkersville, Inc., Walkersville, Md.) supplemented with 1:100 diluted HL-1 supplement (Lonza Walkersille, Inc.) supplemented with ascorbate and L-glutamine as described above 10,000 U/ml penicillin G, 10,000 U/ml streptomycin sulphate and 25 μg/ml amphotericin B.
- Both calf and human juvenile cartilage explants became bigger and thicker over time. On average, a calf cartilage piece with a 1.5 mm diameter and 1 mm thickness increased 0.6 mm to 1 mm in diameter, and 0.5 to 0.8 mm in thickness over eight weeks of culture (
FIG. 5 ). The cultured cartilage explants did not expand uniformly (FIG. 6 ). At the surface of the explant adjacent to the surface of the culture plate (“bottom surface” of the explant), the explant expanded more rapidly than at the upper surface, resulting in an asymmetric, generally cylindrical shape with a smaller upper surface relative to a bigger bottom surface, resulting in newly formed tissue appearing as a ring-like structure surrounding the original piece. Spatial reorientation of an explant piece in culture resulted in the same effect on the former upper surface reoriented as the bottom surface. An explant piece flipped over following faster expansion of the initial bottom surface, resulted in comparably rapid expansion of the new bottom surface, so that the resulting explant ended up with two “bigger” surfaces on both sides. Spatial reorientation thus may provide a method of controlling/directing the orientation and shape of cartilage explant expansion. - Interactions among the cartilage pieces were generated as early as day 5 of calf cartilage culture (
FIG. 7 ) or day 7 of human juvenile cartilage culture (FIG. 8 ). These tissue cultures demonstrated that two cartilage pieces were able to structurally integrate to each other only when they were in close proximity, 1 mm or less than 1 mm apart. This occurred in one of two ways: (a) the pieces were placed in contact with each other at the beginning, or (b) the pieces were placed no more than 1 mm apart and the newly formed tissue by the migrated cells integrated with both explants to form a larger piece of tissue over time (FIG. 9 ). - Initiation of Inter-Piece Interactions:
- During cell migration, some cells migrated into the area between two cartilage pieces and produced extracellular matrix (ECM) simultaneously. The newly formed ECM along with the embedded cells generated the new inter-piece interactions which bind, adhere or “glue” these two pieces together (
FIGS. 10 and 11 ). Over time, more and more cells migrated onto the bridge area between these two pieces. In addition, the cells that were already embedded inside the ECM continued to proliferated. As a result, the ECM became denser and the inter-piece interactions became thicker and wider, containing multiple layers of ECM and cells embedded therein (FIGS. 12 , 13 and 14), and structurally integrated with the surrounding explanted tissue. The structure of the newly formed inter-piece interaction was found to be similar to the original cartilage tissue, based on the gross and histological observation (FIG. 15 ). In contrast, those cartilage explant pieces that were placed more than 1 mm apart were unable to integrate together. Instead, they were surrounded by the migrating and proliferating cells (FIG. 16 ). The cells accumulated next to the cartilage piece, where they piled up as multiple layers and reached almost the same height of the original piece at 10 weeks of culture (FIG. 17 ). - Calf cartilage explants were harvested from five different locations of knee joint: trochlea, trochlea groove, femoral condyle, central tibial plateau and peripheral tibial plateau. The pieces of calf cartilage from different sources were placed according to methods in Example 1. No significant difference was observed on cell migration, cartilage explant expansion and integration among the calf cartilage explants harvested from different locations of knee joint (
FIG. 18 ). Further evaluation was carried out with different sizes of calf cartilage explants. Calf cartilage explants of 1.5 mm, 2 mm, 3 mm and 4 mm in diameter were prepared and cultured according to methods as otherwise described in Example 1. No significant difference was observed on cell migration, cartilage explant expansion and integration among different sizes of calf cartilage explants (FIG. 19 ). - While there was no significant difference between ULA (ultra low attachment) and TC (regular tissue culture) plates on cell migration, cartilage explant growth and integration, significant differences were observed between these two plates on the phenotype of the migrated cells: on TC plates, the migrated cells proliferated and attached to the bottom areas of the plates. The over confluent cells formed multiple layers. The cells on the bottom layers became stretched showing fibroblast-like phenotype, whereas the cells on the top layer still maintained their original round shape showing the typical phenotype of chondrocytes. On ULA plates, instead of attaching to the bottom of the plates, the migrated cells attached to each other and formed cell clusters. Even though some cells on the bottom of the clusters became stretched and attached to the plates, the majority of the cells in the cluster still maintain their original round shapes (
FIG. 20 ). - One skilled in the art would readily appreciate that the methods described in the present disclosure are well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods, procedures, treatments, described herein are merely representative and exemplary, and are not intended as limitations on the scope of the invention. It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the present disclosure disclosed herein without departing from the scope and spirit of the invention.
- All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the present disclosure pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.
Claims (18)
1-20. (canceled)
21. A method of making expanded cartilage tissue, the method comprising:
a) placing a plurality of cartilage tissue pieces on a solid support at an inter-piece distance of 1 mm or less, wherein each cartilage tissue piece has an initial volume of less than 1 mm3; and
b) culturing the plurality of cartilage tissue pieces on the solid support for a time and under conditions sufficient for each cartilage tissue piece to attain an expanded volume of at least 1 mm3.
22. The method of claim 21 , wherein the average volume of expanded cartilage tissue pieces is at least 1.5 mm3.
23. The method of claim 21 , wherein the average volume of expanded cartilage tissue pieces is at least 2.0 mm3.
24. The method of claim 21 , wherein each expanded tissue piece contacts at least one other expanded tissue piece.
25. The method of claim 21 , wherein the cartilage tissue pieces comprise donor cartilage tissue.
26. The method of claim 25 , wherein the donor cartilage tissue is allogeneic to a mammalian recipient of the plurality of expanded cartilage tissue pieces.
27. The method of claim 21 , wherein the cartilage tissue pieces comprise engineered cartilage tissue.
28. The method of claim 21 , wherein the cartilage tissue pieces comprise human juvenile cartilage tissue.
29. The method of claim 21 , wherein the culturing comprises culturing in a culture medium.
30. The method of claim 29 , wherein the culture medium is serum-free.
31. The method of claim 29 , wherein the culture medium comprises at least one additive.
32. The method of claim 31 , wherein the at least one additive comprises cells.
33. The method of claim 32 , wherein the cells are at least one of chondrocytes, progenitor cells, or stem cells.
34. The method of claim 31 , wherein the at least one additive comprises at least one bioactive agent.
35. The method of claim 34 , wherein the at least one bioactive agent is at least one of a hormone, a growth factor or a cytokine.
36. A method of making expanded cartilage tissue, the method comprising culturing a plurality of cartilage tissue pieces on a solid support, wherein each cartilage tissue piece has an initial volume of less than 1 mm3, for a time and under conditions sufficient for each tissue piece to attain an expanded volume of at least 1 mm3.
37. The expanded cartilage tissue made by the method of claim 21 .
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/799,452 US20140178343A1 (en) | 2012-12-21 | 2013-03-13 | Supports and methods for promoting integration of cartilage tissue explants |
| US14/299,314 US10167447B2 (en) | 2012-12-21 | 2014-06-09 | Supports and methods for promoting integration of cartilage tissue explants |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740787P | 2012-12-21 | 2012-12-21 | |
| US13/799,452 US20140178343A1 (en) | 2012-12-21 | 2013-03-13 | Supports and methods for promoting integration of cartilage tissue explants |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/299,314 Division US10167447B2 (en) | 2012-12-21 | 2014-06-09 | Supports and methods for promoting integration of cartilage tissue explants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20140178343A1 true US20140178343A1 (en) | 2014-06-26 |
Family
ID=50974896
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/799,452 Abandoned US20140178343A1 (en) | 2012-12-21 | 2013-03-13 | Supports and methods for promoting integration of cartilage tissue explants |
| US14/299,314 Expired - Fee Related US10167447B2 (en) | 2012-12-21 | 2014-06-09 | Supports and methods for promoting integration of cartilage tissue explants |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/299,314 Expired - Fee Related US10167447B2 (en) | 2012-12-21 | 2014-06-09 | Supports and methods for promoting integration of cartilage tissue explants |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US20140178343A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9138318B2 (en) | 2007-04-12 | 2015-09-22 | Zimmer, Inc. | Apparatus for forming an implant |
| US10167447B2 (en) | 2012-12-21 | 2019-01-01 | Zimmer, Inc. | Supports and methods for promoting integration of cartilage tissue explants |
| US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL240714B1 (en) * | 2019-08-02 | 2022-05-23 | Arthec Spolka Z Ograniczona Odpowiedzialnoscia | Method of conducing in vitro chondrocyte cell culture to obtain material for treatment of articular cartilage defects |
| FR3124067B1 (en) * | 2021-06-17 | 2023-05-26 | Palingen | Implantable device comprising external mobilization means for the formation of articular cartilage |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050032015A1 (en) * | 2003-08-07 | 2005-02-10 | Mcsurdy David W. | System and method for palatal expansion |
| US20070184550A1 (en) * | 2005-08-02 | 2007-08-09 | Satoshi Miyauchi | Artificial cartilage tissue and production method thereof |
Family Cites Families (504)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1347622A (en) | 1919-03-29 | 1920-07-27 | Arthur E Deininger | Vaccine-injector |
| US2533004A (en) | 1943-10-27 | 1950-12-05 | John D Ferry | Fibrin clots and methods for preparing the same |
| US2621145A (en) | 1949-08-17 | 1952-12-09 | Machteld E Sano | Bone mat compositions |
| USRE28093E (en) | 1962-02-28 | 1974-07-30 | Wound-healing cartilage powder | |
| US3400199A (en) | 1965-02-26 | 1968-09-03 | Leslie L. Balassa | Wound-healing cartilage powder |
| US3302289A (en) | 1963-10-21 | 1967-02-07 | Lawrence A Spaulding | Impression and bite tray for dentistry |
| US3478146A (en) | 1965-02-26 | 1969-11-11 | Leslie L Balassa | Wound-healing cartilage powder extracting process |
| US3476855A (en) | 1965-02-26 | 1969-11-04 | Leslie L Balassa | Sterilizing and enhancing activity of a finely divided cartilage powder |
| US3474146A (en) | 1967-01-03 | 1969-10-21 | Stauffer Chemical Co | Fluorine-containing ethyl disulfides |
| US3772432A (en) | 1971-01-11 | 1973-11-13 | Lescarden Ltd | Cartilage compositions for dental use |
| US3966908A (en) | 1973-11-29 | 1976-06-29 | Lescarden Ltd. | Method of treating degenerative joint afflictions |
| GB2023314B (en) | 1978-06-15 | 1982-10-06 | Ibm | Digital data processing systems |
| US4350682A (en) | 1979-05-11 | 1982-09-21 | Lescarden Ltd. | Cartilage extraction processes and products |
| US4440680A (en) | 1980-09-24 | 1984-04-03 | Seton Company | Macromolecular biologically active collagen articles |
| DE3105624A1 (en) | 1981-02-16 | 1982-09-02 | Hormon-Chemie München GmbH, 8000 München | MATERIAL FOR SEALING AND HEALING Wounds |
| US4466435A (en) | 1981-09-04 | 1984-08-21 | Murray William M | Bone cement nozzle and method |
| US4479271A (en) | 1981-10-26 | 1984-10-30 | Zimmer, Inc. | Prosthetic device adapted to promote bone/tissue ingrowth |
| US5656587A (en) | 1982-09-24 | 1997-08-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Promotion of cell proliferation by use of transforming growth factor beta (TGF-β) |
| US5002582A (en) | 1982-09-29 | 1991-03-26 | Bio-Metric Systems, Inc. | Preparation of polymeric surfaces via covalently attaching polymers |
| DE3247387C2 (en) | 1982-12-22 | 1984-11-22 | Rolf Prof. Dr.med. 7400 Tübingen Hettich | Method for producing a transplant and device for carrying out the method |
| US4566138A (en) | 1983-03-08 | 1986-01-28 | Zimmer, Inc. | Prosthetic device with spacers |
| US4911720A (en) | 1983-03-10 | 1990-03-27 | Collier John P | Particular surface replacement prosthesis |
| IL68218A (en) | 1983-03-23 | 1985-12-31 | Univ Ramot | Compositions for cartilage repair comprising embryonal chondrocytes |
| US4522096A (en) | 1983-06-16 | 1985-06-11 | R. J. Reynolds Tobacco Company | Dicing apparatus for sheet material |
| GB8318483D0 (en) | 1983-07-08 | 1983-08-10 | Zimmer Deloro Surgical Ltd | Skeletal implants |
| EP0133934A3 (en) | 1983-07-29 | 1985-09-18 | NIKEPHARMA S.r.l. | Pharmacologically active 1,3,4-thiadiazol-(3,2-a)-thieno-(2,3-d)-pyrimidin-5-(h)one derivatives |
| JPS60109781A (en) | 1983-08-09 | 1985-06-15 | Honda Motor Co Ltd | Synchronous operation control device |
| US4641651A (en) | 1983-09-22 | 1987-02-10 | Card George W | Cartilage punch and modified prosthesis in tympanoplasty |
| JPS59135054A (en) | 1983-10-03 | 1984-08-03 | 朝倉 由純 | Hip joint |
| AT389815B (en) | 1984-03-09 | 1990-02-12 | Immuno Ag | METHOD FOR INACTIVATING VARIABLE FILTERABLE DISEASERS IN BLOOD PRODUCTS |
| US4609551A (en) | 1984-03-20 | 1986-09-02 | Arnold Caplan | Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites |
| GB8413319D0 (en) | 1984-05-24 | 1984-06-27 | Oliver Roy Frederick | Biological material |
| US4863475A (en) | 1984-08-31 | 1989-09-05 | Zimmer, Inc. | Implant and method for production thereof |
| US4928603A (en) | 1984-09-07 | 1990-05-29 | The Trustees Of Columbia University In The City Of New York | Method of preparing a cryoprecipitated suspension and use thereof |
| US4627879A (en) | 1984-09-07 | 1986-12-09 | The Trustees Of Columbia University In The City Of New York | Fibrin adhesive prepared as a concentrate from single donor fresh frozen plasma |
| US4678470A (en) | 1985-05-29 | 1987-07-07 | American Hospital Supply Corporation | Bone-grafting material |
| US4660755A (en) | 1985-09-09 | 1987-04-28 | Zimmer, Inc. | Method for constructing a surgical implant |
| US4656137A (en) | 1985-09-12 | 1987-04-07 | Lescarden Inc | Method of processing animal cartilage |
| GB8626226D0 (en) | 1985-11-14 | 1986-12-03 | Ici Plc | Metal matrix composites |
| US5902741A (en) | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
| US4963489A (en) | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| US5032508A (en) | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| US4714457A (en) | 1986-09-15 | 1987-12-22 | Robert Alterbaum | Method and apparatus for use in preparation of fibrinogen from a patient's blood |
| US5254471A (en) | 1986-10-06 | 1993-10-19 | Toray Industries, Inc. | Carrier for cell culture |
| US5041138A (en) | 1986-11-20 | 1991-08-20 | Massachusetts Institute Of Technology | Neomorphogenesis of cartilage in vivo from cell culture |
| GB8708009D0 (en) | 1987-04-03 | 1987-05-07 | Clayton Found Res | Injectable soft tissue augmentation materials |
| US4846835A (en) | 1987-06-15 | 1989-07-11 | Grande Daniel A | Technique for healing lesions in cartilage |
| US4952403A (en) | 1987-06-19 | 1990-08-28 | President And Fellows Of Harvard College | Implants for the promotion of healing of meniscal tissue |
| US5306311A (en) | 1987-07-20 | 1994-04-26 | Regen Corporation | Prosthetic articular cartilage |
| US5681353A (en) | 1987-07-20 | 1997-10-28 | Regen Biologics, Inc. | Meniscal augmentation device |
| US5018285A (en) | 1987-08-24 | 1991-05-28 | Zimmer, Inc. | Method of constructing prosthetic implant with wrapped porous surface |
| US5013324A (en) | 1987-08-24 | 1991-05-07 | Zimmer, Inc. | Prosthetic implant with wrapped porous surface |
| US4851354A (en) | 1987-12-07 | 1989-07-25 | Trustees Of The University Of Pennsylvania | Apparatus for mechanically stimulating cells |
| US5139527A (en) | 1987-12-17 | 1992-08-18 | Immuno Aktiengesellschaft | Biologic absorbable implant material for filling and closing soft tissue cavities and method of its preparation |
| GB8803697D0 (en) | 1988-02-17 | 1988-03-16 | Deltanine Research Ltd | Clinical developments using amniotic membrane cells |
| US5219363A (en) | 1988-03-22 | 1993-06-15 | Zimmer, Inc. | Bone implant |
| US5053050A (en) | 1988-04-29 | 1991-10-01 | Samuel Itay | Compositions for repair of cartilage and bone |
| US4904259A (en) | 1988-04-29 | 1990-02-27 | Samuel Itay | Compositions and methods for repair of cartilage and bone |
| US5290552A (en) | 1988-05-02 | 1994-03-01 | Matrix Pharmaceutical, Inc./Project Hear | Surgical adhesive material |
| ES2064439T3 (en) | 1988-05-02 | 1995-02-01 | Project Hear | SURGICAL ADHESIVE MATERIAL. |
| US4950483A (en) | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| US5080674A (en) | 1988-09-08 | 1992-01-14 | Zimmer, Inc. | Attachment mechanism for securing an additional portion to an implant |
| US5565519A (en) | 1988-11-21 | 1996-10-15 | Collagen Corporation | Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications |
| US5475052A (en) | 1988-11-21 | 1995-12-12 | Collagen Corporation | Collagen-synthetic polymer matrices prepared using a multiple step reaction |
| DE58905636D1 (en) | 1989-03-23 | 1993-10-21 | Straumann Inst Ag | Metallic implant. |
| US5130418A (en) | 1989-05-02 | 1992-07-14 | California Biotechnology Inc. | Method to stabilize basic fibroblast growth factor |
| US5226877A (en) | 1989-06-23 | 1993-07-13 | Epstein Gordon H | Method and apparatus for preparing fibrinogen adhesive from whole blood |
| CA2020654A1 (en) | 1989-07-07 | 1991-01-08 | Yohko Akiyama | Stabilized fgf composition and production thereof |
| DE69004098T2 (en) | 1989-08-10 | 1994-08-04 | Gore & Ass | MEDICAL DISPENSING SYSTEM FOR TISSUE ADHESIVE COMPONENTS. |
| US5290558A (en) | 1989-09-21 | 1994-03-01 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
| GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| US4997445A (en) | 1989-12-08 | 1991-03-05 | Zimmer, Inc. | Metal-backed prosthetic implant with enhanced bonding of polyethylene portion to metal base |
| US5067964A (en) | 1989-12-13 | 1991-11-26 | Stryker Corporation | Articular surface repair |
| US4997444A (en) | 1989-12-28 | 1991-03-05 | Zimmer, Inc. | Implant having varying modulus of elasticity |
| US5030215A (en) | 1990-01-03 | 1991-07-09 | Cryolife, Inc. | Preparation of fibrinogen/factor XIII precipitate |
| US5514153A (en) | 1990-03-02 | 1996-05-07 | General Surgical Innovations, Inc. | Method of dissecting tissue layers |
| US5345927A (en) | 1990-03-02 | 1994-09-13 | Bonutti Peter M | Arthroscopic retractors |
| US5217954A (en) | 1990-04-04 | 1993-06-08 | Scios Nova Inc. | Formulations for stabilizing fibroblast growth factor |
| US5593425A (en) | 1990-06-28 | 1997-01-14 | Peter M. Bonutti | Surgical devices assembled using heat bonable materials |
| US5269785A (en) | 1990-06-28 | 1993-12-14 | Bonutti Peter M | Apparatus and method for tissue removal |
| US6464713B2 (en) | 1990-06-28 | 2002-10-15 | Peter M. Bonutti | Body tissue fastening |
| US6990982B1 (en) | 1990-06-28 | 2006-01-31 | Bonutti Ip, Llc | Method for harvesting and processing cells from tissue fragments |
| US5069881A (en) | 1990-07-10 | 1991-12-03 | Mobay Corporation | Device and method for applying adhesives |
| US5067963A (en) | 1990-08-21 | 1991-11-26 | Washington University | Method of making live autogenous skeletal replacement parts |
| US5948384A (en) | 1990-09-14 | 1999-09-07 | Syngenix Limited | Particulate agents |
| US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| CA2041430C (en) | 1990-10-30 | 2002-11-26 | Jack Eldon Parr | Orthopaedic implant device |
| US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
| US5226914A (en) | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
| US6054122A (en) | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| DE69132918T2 (en) | 1990-11-27 | 2002-10-31 | American National Red Cross, Washington | TISSUE COVER AND GROWTH FACTOR CONTAINING CONNECTIONS TO PROMOTE ACCELERATED Wounds Healing |
| US6559119B1 (en) | 1990-11-27 | 2003-05-06 | Loyola University Of Chicago | Method of preparing a tissue sealant-treated biomedical material |
| WO1992009697A1 (en) | 1990-11-30 | 1992-06-11 | Celtrix Laboratories, Inc. | USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR |
| CA2055966C (en) | 1990-12-19 | 1995-08-01 | Oresta Natalia Fedun | Cell culture insert |
| US5198308A (en) | 1990-12-21 | 1993-03-30 | Zimmer, Inc. | Titanium porous surface bonded to a cobalt-based alloy substrate in an orthopaedic implant device |
| US5853746A (en) | 1991-01-31 | 1998-12-29 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier |
| US5206023A (en) | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
| AT402891B (en) | 1991-06-20 | 1997-09-25 | Immuno Ag | METHOD FOR PRODUCING AN INACTIVATED BLOOD PRODUCT |
| US5356629A (en) | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
| US6773458B1 (en) | 1991-07-24 | 2004-08-10 | Baxter International Inc. | Angiogenic tissue implant systems and methods |
| US5092887A (en) | 1991-08-12 | 1992-03-03 | El Gendler | Artificial ligament produced from demineralized bone for the replacement and augmentation of ligaments, tendons and other fibrous connective tissue |
| US5329846A (en) | 1991-08-12 | 1994-07-19 | Bonutti Peter M | Tissue press and system |
| US6503277B2 (en) | 1991-08-12 | 2003-01-07 | Peter M. Bonutti | Method of transplanting human body tissue |
| US5270300A (en) | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
| US6919067B2 (en) | 1991-09-13 | 2005-07-19 | Syngenix Limited | Compositions comprising a tissue glue and therapeutic agents |
| US5281422A (en) | 1991-09-24 | 1994-01-25 | Purdue Research Foundation | Graft for promoting autogenous tissue growth |
| ATE152631T1 (en) | 1991-10-30 | 1997-05-15 | Massachusetts Inst Technology | PREVASCULARIZED POLYMER IMPLANTS FOR ORGAN TRANSPLANTATION |
| US5482929A (en) | 1991-12-26 | 1996-01-09 | Kaken Pharmaceutical Co., Ltd. | Composition of stabilized fibroblast growth factor |
| US6818008B1 (en) | 1992-01-07 | 2004-11-16 | Cch Associates, Inc. | Percutaneous puncture sealing method |
| US5314476A (en) | 1992-02-04 | 1994-05-24 | Osteotech, Inc. | Demineralized bone particles and flowable osteogenic composition containing same |
| US5876452A (en) | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
| US5236457A (en) | 1992-02-27 | 1993-08-17 | Zimmer, Inc. | Method of making an implant having a metallic porous surface |
| US5282861A (en) | 1992-03-11 | 1994-02-01 | Ultramet | Open cell tantalum structures for cancellous bone implants and cell and tissue receptors |
| US5326357A (en) | 1992-03-18 | 1994-07-05 | Mount Sinai Hospital Corporation | Reconstituted cartridge tissue |
| DK83092D0 (en) | 1992-06-24 | 1992-06-24 | Unes As | PROCEDURE FOR THE EXTRACTION OF THROMBIN |
| US5312417A (en) | 1992-07-29 | 1994-05-17 | Wilk Peter J | Laparoscopic cannula assembly and associated method |
| CN1091315A (en) | 1992-10-08 | 1994-08-31 | E·R·斯奎布父子公司 | Fibrin sealant compositions and methods of use thereof |
| US5275826A (en) | 1992-11-13 | 1994-01-04 | Purdue Research Foundation | Fluidized intestinal submucosa and its use as an injectable tissue graft |
| US5387243A (en) | 1992-11-23 | 1995-02-07 | Zimmer, Inc. | Method for converting a cementable implant to a press fit implant |
| US5443454A (en) | 1992-12-09 | 1995-08-22 | Terumo Kabushiki Kaisha | Catheter for embolectomy |
| US5723011A (en) | 1992-12-21 | 1998-03-03 | Zimmer, Inc. | Prosthetic implant and method of making same |
| US5749968A (en) | 1993-03-01 | 1998-05-12 | Focal, Inc. | Device for priming for improved adherence of gels to substrates |
| US5330974A (en) | 1993-03-01 | 1994-07-19 | Fibratek, Inc. | Therapeutic fibrinogen compositions |
| DE4306661C2 (en) | 1993-03-03 | 1995-04-20 | Michael Dipl Biol Sittinger | Process for producing an implant from cell cultures |
| US5443510A (en) | 1993-04-06 | 1995-08-22 | Zimmer, Inc. | Porous coated implant and method of making same |
| EP2025353A2 (en) | 1993-04-30 | 2009-02-18 | Massachusetts Institute of Technology | Injectable polysaccharide-cell compositions |
| US5709854A (en) | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
| US5549904A (en) | 1993-06-03 | 1996-08-27 | Orthogene, Inc. | Biological adhesive composition and method of promoting adhesion between tissue surfaces |
| US5795780A (en) | 1993-06-23 | 1998-08-18 | Bristol-Myers Squibb Company | Method of use of autologous thrombin blood fraction in a cell culture with keratinocytes |
| US5405742A (en) | 1993-07-16 | 1995-04-11 | Cyromedical Sciences, Inc. | Solutions for tissue preservation and bloodless surgery and methods using same |
| EP0641007A3 (en) | 1993-08-31 | 1995-06-21 | Samsung Display Devices Co Ltd | Direct-heating-type dispenser cathode structure. |
| DE4338129A1 (en) | 1993-11-08 | 1995-05-11 | Zimmer Ag | Process for polymer melt filtration |
| US5890898A (en) | 1993-11-08 | 1999-04-06 | Wada; Eric Minoru | Infection control guard for dental air-water syringes |
| US5888491A (en) | 1993-12-06 | 1999-03-30 | Minnesota Mining And Manufacturing Company | Optionally crosslinkable coatings, compositions and methods of use |
| US6312668B2 (en) | 1993-12-06 | 2001-11-06 | 3M Innovative Properties Company | Optionally crosslinkable coatings, compositions and methods of use |
| IL112580A0 (en) | 1994-02-24 | 1995-05-26 | Res Dev Foundation | Amniotic membrane graft of wrap to prevent adhesions or bleeding of internal organs |
| KR100365573B1 (en) | 1994-03-14 | 2004-08-25 | 크라이어라이프, 인크. | Transplantation tissue and its manufacturing method |
| US5461953A (en) | 1994-03-25 | 1995-10-31 | Mccormick; James B. | Multi-dimension microtome sectioning device |
| US5504300A (en) | 1994-04-18 | 1996-04-02 | Zimmer, Inc. | Orthopaedic implant and method of making same |
| US6025334A (en) | 1994-04-28 | 2000-02-15 | Les Laboratoires Aeterna Inc. | Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof |
| US5618925A (en) | 1994-04-28 | 1997-04-08 | Les Laboratories Aeterna Inc. | Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof |
| US5723331A (en) | 1994-05-05 | 1998-03-03 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
| WO1998020939A2 (en) | 1996-11-15 | 1998-05-22 | Advanced Bio Surfaces, Inc. | Biomaterial system for in situ tissue repair |
| US6140452A (en) | 1994-05-06 | 2000-10-31 | Advanced Bio Surfaces, Inc. | Biomaterial for in situ tissue repair |
| US5888220A (en) | 1994-05-06 | 1999-03-30 | Advanced Bio Surfaces, Inc. | Articulating joint repair |
| US5556429A (en) | 1994-05-06 | 1996-09-17 | Advanced Bio Surfaces, Inc. | Joint resurfacing system |
| US5906827A (en) | 1994-06-03 | 1999-05-25 | Creative Biomolecules, Inc. | Matrix for the manufacture of autogenous replacement body parts |
| JP3028852B2 (en) | 1994-06-24 | 2000-04-04 | ロシュ ダイアグノスティックス コーポレーション | Purified mixture of collagenase and two other proteases obtained from Histolyticus |
| DE69531869T2 (en) | 1994-07-21 | 2004-07-22 | Sirus Pharmaceuticals Ltd. | COMPOSITION CONTAINING A TISSUE ADHESIVE AND AN IMMOBILIZED THERAPEUTIC ACTIVE PARTICLE |
| WO1996003160A1 (en) | 1994-07-26 | 1996-02-08 | Children's Medical Center Corporation | Fibrin-cell suspension for construction of new tissue |
| US5516532A (en) | 1994-08-05 | 1996-05-14 | Children's Medical Center Corporation | Injectable non-immunogenic cartilage and bone preparation |
| US5769899A (en) | 1994-08-12 | 1998-06-23 | Matrix Biotechnologies, Inc. | Cartilage repair unit |
| CH689725A5 (en) | 1994-09-08 | 1999-09-30 | Franz Dr Sutter | Condyle prosthesis. |
| US5496375A (en) | 1994-09-14 | 1996-03-05 | Zimmer, Inc. | Prosthetic implant with circumferential porous pad having interlocking tabs |
| US5824093A (en) | 1994-10-17 | 1998-10-20 | Raymedica, Inc. | Prosthetic spinal disc nucleus |
| US5654166A (en) | 1994-11-09 | 1997-08-05 | Kurth; Gerhard P. | Process of preparing hormone-free bovine cartilage for dosage form |
| US6110212A (en) | 1994-11-15 | 2000-08-29 | Kenton W. Gregory | Elastin and elastin-based materials |
| US5585007A (en) | 1994-12-07 | 1996-12-17 | Plasmaseal Corporation | Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant |
| US5632432A (en) | 1994-12-19 | 1997-05-27 | Ethicon Endo-Surgery, Inc. | Surgical instrument |
| DE4445891A1 (en) | 1994-12-22 | 1996-06-27 | Boehringer Mannheim Gmbh | Recombinant proteinase from Clostridium histolyticum and its use for the isolation of cells and cell assemblies |
| US6599515B1 (en) | 1995-01-16 | 2003-07-29 | Baxter International Inc. | Fibrin porous structure |
| US6965014B1 (en) | 1996-01-16 | 2005-11-15 | Baxter International Inc. | Fibrin material and method for producing and using the same |
| US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
| ES2150096T3 (en) | 1995-01-27 | 2000-11-16 | Coloplast As | A DRESSING. |
| US6485723B1 (en) | 1995-02-10 | 2002-11-26 | Purdue Research Foundation | Enhanced submucosal tissue graft constructs |
| US5713374A (en) | 1995-02-10 | 1998-02-03 | The Hospital For Joint Diseases Orthopaedic Institute | Fixation method for the attachment of wound repair materials to cartilage defects |
| US6080194A (en) | 1995-02-10 | 2000-06-27 | The Hospital For Joint Disease Orthopaedic Institute | Multi-stage collagen-based template or implant for use in the repair of cartilage lesions |
| US5695998A (en) | 1995-02-10 | 1997-12-09 | Purdue Research Foundation | Submucosa as a growth substrate for islet cells |
| US5879398A (en) | 1995-02-14 | 1999-03-09 | Zimmer, Inc. | Acetabular cup |
| US20030039695A1 (en) | 2001-08-10 | 2003-02-27 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Collagen carrier of therapeutic genetic material, and method |
| US20050186673A1 (en) | 1995-02-22 | 2005-08-25 | Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie | Collagen carrier of therapeutic genetic material, and method |
| US5782835A (en) | 1995-03-07 | 1998-07-21 | Innovasive Devices, Inc. | Apparatus and methods for articular cartilage defect repair |
| EP0734736A1 (en) | 1995-03-31 | 1996-10-02 | Toyo Boseki Kabushiki Kaisha | Medical device and method for producing the same |
| US5840713A (en) | 1995-04-03 | 1998-11-24 | Weisz; Paul B. | Therapy for tissue membrane insufficiency |
| US5643192A (en) | 1995-04-06 | 1997-07-01 | Hamilton Civic Hospitals Research Development, Inc. | Autologous fibrin glue and methods for its preparation and use |
| US5554389A (en) | 1995-04-07 | 1996-09-10 | Purdue Research Foundation | Urinary bladder submucosa derived tissue graft |
| US5714371A (en) | 1995-05-12 | 1998-02-03 | Schering Corporation | Method for refolding insoluble aggregates of hepatitis C virus protease |
| US5902785A (en) | 1995-06-06 | 1999-05-11 | Genetics Institute, Inc. | Cartilage induction by bone morphogenetic proteins |
| US5655546A (en) | 1995-06-07 | 1997-08-12 | Halpern; Alan A. | Method for cartilage repair |
| US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
| US5674292A (en) | 1995-06-07 | 1997-10-07 | Stryker Corporation | Terminally sterilized osteogenic devices and preparation thereof |
| PT840748E (en) | 1995-07-25 | 2003-08-29 | Novartis Ag | TRANSFORMANT GROWTH FACTOR CRYSTALS |
| US5535810A (en) | 1995-07-28 | 1996-07-16 | Zimmer, Inc. | Cast orthopaedic implant and method of making same |
| US5944755A (en) | 1995-09-15 | 1999-08-31 | Crosscart, Inc. | Articular cartilage xenografts |
| US5782915A (en) | 1995-09-15 | 1998-07-21 | Stone; Kevin R. | Articular cartilage heterografts |
| US6132674A (en) | 1995-10-12 | 2000-10-17 | Bristol-Myers Squibb Company | Method of making an orthopaedic implant having a porous surface |
| US5734959A (en) | 1995-10-12 | 1998-03-31 | Zimmer, Inc. | Method of making an orthopaedic implant having a porous surface using an organic binder |
| ATE258810T1 (en) | 1995-11-09 | 2004-02-15 | Univ Massachusetts | RESTORATION OF TISSUE SURFACE USING HYDROGEL CELL COMPOSITIONS |
| JP4193917B2 (en) | 1995-12-18 | 2008-12-10 | アンジオデバイス インターナショナル ゲーエムベーハー | Crosslinked polymer composition and method of use thereof |
| US6833408B2 (en) | 1995-12-18 | 2004-12-21 | Cohesion Technologies, Inc. | Methods for tissue repair using adhesive materials |
| US5989888A (en) | 1996-01-24 | 1999-11-23 | Roche Diagnostics Corporation | Purified mixture of collagenase I, collagenase II and two other proteases |
| US5639280A (en) | 1996-02-02 | 1997-06-17 | Zimmer, Inc. | Constraining ring for a hip cup |
| US5842477A (en) | 1996-02-21 | 1998-12-01 | Advanced Tissue Sciences, Inc. | Method for repairing cartilage |
| US6087553A (en) | 1996-02-26 | 2000-07-11 | Implex Corporation | Implantable metallic open-celled lattice/polyethylene composite material and devices |
| US5755791A (en) | 1996-04-05 | 1998-05-26 | Purdue Research Foundation | Perforated submucosal tissue graft constructs |
| DE19617369A1 (en) | 1996-04-30 | 1997-11-06 | Immuno Ag | Storage-stable fibrinogen preparations |
| DE19781869T1 (en) | 1996-04-30 | 2000-03-16 | Medtronic Inc | Process for the production of an autologous fibrin hemostatic agent |
| WO2000062828A1 (en) | 1996-04-30 | 2000-10-26 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
| US6632648B1 (en) | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
| EP0906128A1 (en) | 1996-05-28 | 1999-04-07 | 1218122 Ontario Inc. | Resorbable implant biomaterial made of condensed calcium phosphate particles |
| WO1997046665A1 (en) | 1996-06-04 | 1997-12-11 | Sulzer Orthopedics Ltd. | Method for making cartilage and implants |
| JP4625548B2 (en) | 1996-07-01 | 2011-02-02 | ウニベルジテート ユートレヒト | Hydrolyzable hydrogels for controlled release |
| JP3638614B2 (en) | 1996-07-25 | 2005-04-13 | ジェンザイム・コーポレーション | Chondrocyte medium composition and culture method |
| JP3492857B2 (en) | 1996-07-30 | 2004-02-03 | 京セラ株式会社 | Method for improving wear resistance of polyvinyl alcohol hydrogel |
| US6666892B2 (en) | 1996-08-23 | 2003-12-23 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
| US5989269A (en) | 1996-08-30 | 1999-11-23 | Vts Holdings L.L.C. | Method, instruments and kit for autologous transplantation |
| US6120514A (en) | 1996-08-30 | 2000-09-19 | Vts Holdings, Llc | Method and kit for autologous transplantation |
| US5827217A (en) | 1996-09-04 | 1998-10-27 | Silver; Frederick H. | Process and apparatus for harvesting tissue for processing tissue and process and apparatus for re-injecting processed tissue |
| US5964805A (en) | 1997-02-12 | 1999-10-12 | Stone; Kevin R. | Method and paste for articular cartilage transplantation |
| US5921987A (en) | 1996-09-13 | 1999-07-13 | Depuy Orthopaedic Technology, Inc. | Articular cartilage transplant instrument set |
| IT1284550B1 (en) | 1996-09-18 | 1998-05-21 | Flavio Tarantino | PROCEDURE FOR THE PREPARATION OF AUTOLOGOUS FIBRIN GLUE FOR SURGICAL USE |
| NL1004276C2 (en) | 1996-10-15 | 1998-04-20 | Willem Marie Ysebaert | Methods for manufacturing skin islets, for moving skin or islets, for spreading skin isles and applying them to a burn, as well as a holder, cutting frame, cutting table, counter carrier, clamping member, membrane, transporter and spreader for use in such methods. |
| US5919702A (en) | 1996-10-23 | 1999-07-06 | Advanced Tissue Science, Inc. | Production of cartilage tissue using cells isolated from Wharton's jelly |
| WO1998022574A2 (en) | 1996-11-19 | 1998-05-28 | Roche Diagnostics Gmbh | Type i recombinant clostridium histolyticum collagenase and its use for isolating cells and cell aggregates |
| US5928945A (en) | 1996-11-20 | 1999-07-27 | Advanced Tissue Sciences, Inc. | Application of shear flow stress to chondrocytes or chondrocyte stem cells to produce cartilage |
| DE19648744A1 (en) | 1996-11-25 | 1998-05-28 | Basf Ag | Process for the preparation of a polymer dispersion by radical aqueous emulsion polymerization with a continuously produced aqueous monomer emulsion |
| US5830741A (en) | 1996-12-06 | 1998-11-03 | Boehringer Mannheim Corporation | Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease |
| FR2757770B1 (en) | 1996-12-30 | 1999-02-26 | Inoteb | PROCESS FOR THE PREPARATION OF A BIOLOGICAL GLUE CAPABLE OF COAGULATING BY SIMPLE ADDITION OF CALCIUM IONS |
| US8882847B2 (en) | 2001-05-25 | 2014-11-11 | Conformis, Inc. | Patient selectable knee joint arthroplasty devices |
| ZA98596B (en) | 1997-01-26 | 1999-07-26 | Horst Mosshammer Von Mosshaim | Table top model hot plate or warming plate appliance. |
| DE19708703C2 (en) | 1997-02-24 | 2002-01-24 | Co Don Ag | Surgical cutlery |
| US6152142A (en) | 1997-02-28 | 2000-11-28 | Tseng; Scheffer C. G. | Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries |
| GB9704749D0 (en) | 1997-03-07 | 1997-04-23 | Univ London | Tissue Implant |
| US6733515B1 (en) | 1997-03-12 | 2004-05-11 | Neomend, Inc. | Universal introducer |
| US5866415A (en) | 1997-03-25 | 1999-02-02 | Villeneuve; Peter E. | Materials for healing cartilage and bone defects |
| DE19713011C2 (en) | 1997-03-27 | 1999-10-21 | Friadent Gmbh | Foil for medical technology |
| JP4394169B2 (en) | 1997-04-04 | 2010-01-06 | バーンズ − ジューウィッシュ・ホスピタル | New cartilage and methods of use |
| US6224893B1 (en) | 1997-04-11 | 2001-05-01 | Massachusetts Institute Of Technology | Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering |
| US6979307B2 (en) | 1997-06-24 | 2005-12-27 | Cascade Medical Enterprises Llc | Systems and methods for preparing autologous fibrin glue |
| IT1292410B1 (en) | 1997-06-24 | 1999-02-08 | Roberto Beretta | READY-TO-USE CONTAINER TO OBTAIN AUTOLOGOUS FIBRIN GLUE |
| US6107085A (en) | 1997-07-11 | 2000-08-22 | Corning Incorporated | Self contained cell growth system |
| ZA987019B (en) | 1997-08-06 | 1999-06-04 | Focal Inc | Hemostatic tissue sealants |
| US6110209A (en) | 1997-08-07 | 2000-08-29 | Stone; Kevin R. | Method and paste for articular cartilage transplantation |
| US6511958B1 (en) | 1997-08-14 | 2003-01-28 | Sulzer Biologics, Inc. | Compositions for regeneration and repair of cartilage lesions |
| EP0896825B1 (en) | 1997-08-14 | 2002-07-17 | Sulzer Innotec Ag | Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors |
| EP1015045A2 (en) | 1997-08-22 | 2000-07-05 | Direct Therapeutics, Inc. | An apparatus for preventing loss of a composition during a medical procedure |
| US20050186283A1 (en) | 1997-10-10 | 2005-08-25 | Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie | Collagen carrier of therapeutic genetic material, and method |
| US6458095B1 (en) | 1997-10-22 | 2002-10-01 | 3M Innovative Properties Company | Dispenser for an adhesive tissue sealant having a housing with multiple cavities |
| CA2307743A1 (en) | 1997-10-30 | 1999-05-14 | The General Hospital Corporation | Bonding of cartilaginous matrices using isolated chondrocytes |
| US20030099620A1 (en) | 1997-10-30 | 2003-05-29 | The General Hospital Corporation | Bonding of cartilaginous matrices using isolated chondrocytes |
| US6080579A (en) | 1997-11-26 | 2000-06-27 | Charlotte-Mecklenburg Hospital Authority | Method for producing human intervertebral disc cells |
| US6187329B1 (en) | 1997-12-23 | 2001-02-13 | Board Of Regents Of The University Of Texas System | Variable permeability bone implants, methods for their preparation and use |
| US5964752A (en) | 1998-02-02 | 1999-10-12 | Stone; Kevin R. | Articular cartilage surface shaping apparatus and method |
| US6437018B1 (en) | 1998-02-27 | 2002-08-20 | Musculoskeletal Transplant Foundation | Malleable paste with high molecular weight buffered carrier for filling bone defects |
| US6143214A (en) | 1998-03-09 | 2000-11-07 | Board Of Regents Of The University Of Texas System | Mixing and dispensing system for rapidly polymerizing materials |
| DE69903800T2 (en) | 1998-03-18 | 2003-10-02 | Massachusetts Institute Of Technology, Cambridge | VASCULARIZED PERFUNDED ARRANGEMENTS FOR MICRO TISSUE AND MICROORGANES |
| US6471958B2 (en) | 1998-03-24 | 2002-10-29 | University Of North Texas Health Science Center | Non-contracting tissue equivalent |
| AU3118499A (en) | 1998-04-03 | 1999-10-25 | Beth Israel Deaconess Medical Center | Soft tissue reconstructor and method of use |
| US20040044408A1 (en) | 1998-04-08 | 2004-03-04 | Hungerford David S. | Cell-culture and polymer constructs |
| US6514522B2 (en) | 1998-04-08 | 2003-02-04 | Chondros, Inc. | Polymer constructs |
| US6886568B2 (en) | 1998-04-08 | 2005-05-03 | The Johns Hopkins University | Method for fabricating cell-containing implants |
| US6378527B1 (en) | 1998-04-08 | 2002-04-30 | Chondros, Inc. | Cell-culture and polymer constructs |
| US6637437B1 (en) | 1998-04-08 | 2003-10-28 | Johns Hopkins University | Cell-culture and polymer constructs |
| EP1084454B1 (en) | 1998-04-21 | 2016-03-09 | University of Connecticut | Free-form nanofabrication using multi-photon excitation |
| US6171610B1 (en) | 1998-04-24 | 2001-01-09 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
| WO1999057817A2 (en) | 1998-04-30 | 1999-11-11 | Koninklijke Philips Electronics N.V. | Code division multiple access transmitter and receiver |
| US6835377B2 (en) * | 1998-05-13 | 2004-12-28 | Osiris Therapeutics, Inc. | Osteoarthritis cartilage regeneration |
| US6132465A (en) | 1998-06-04 | 2000-10-17 | Raymedica, Inc. | Tapered prosthetic spinal disc nucleus |
| US6083383A (en) | 1998-06-25 | 2000-07-04 | Huang; Xun Yang | Apparatus for production of fibrin ogen or fibrin glue |
| US6086593A (en) | 1998-06-30 | 2000-07-11 | Bonutti; Peter M. | Method and apparatus for use in operating on a bone |
| US6045990A (en) | 1998-07-09 | 2000-04-04 | Baust; John M. | Inclusion of apoptotic regulators in solutions for cell storage at low temperature |
| WO2000006216A1 (en) | 1998-07-27 | 2000-02-10 | Focal, Inc. | Universal modular surgical applicator systems |
| US6274090B1 (en) | 1998-08-05 | 2001-08-14 | Thermogenesis Corp. | Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby |
| AU5132199A (en) | 1998-08-13 | 2000-03-06 | Warner-Lambert Company | Electroporation buffer with cryprotective capabilities |
| US6551355B1 (en) | 1998-08-14 | 2003-04-22 | Cambridge Scientific, Inc. | Tissue transplant coated with biocompatible biodegradable polymer |
| KR20040081798A (en) | 1998-08-14 | 2004-09-22 | 페리겐 트란스플란타치온 서비스 인터나치오날 (파우테에스이) 아게 | Methods, instruments and materials for chondrocyte cell transplantation |
| US6099531A (en) | 1998-08-20 | 2000-08-08 | Bonutti; Peter M. | Changing relationship between bones |
| US6530956B1 (en) * | 1998-09-10 | 2003-03-11 | Kevin A. Mansmann | Resorbable scaffolds to promote cartilage regeneration |
| WO2000017321A2 (en) | 1998-09-18 | 2000-03-30 | Massachusetts Institute Of Technology | Use of growth factors and hormones for expansion of mammalian cells and tissue engineering |
| US6140123A (en) | 1998-10-07 | 2000-10-31 | Cedars-Sinai Medical Center | Method for conditioning and cryopreserving cells |
| US6022361A (en) | 1998-10-09 | 2000-02-08 | Biointerventional Corporation | Device for introducing and polymerizing polymeric biomaterials in the human body and method |
| US20030114936A1 (en) | 1998-10-12 | 2003-06-19 | Therics, Inc. | Complex three-dimensional composite scaffold resistant to delimination |
| WO2000029484A1 (en) | 1998-11-17 | 2000-05-25 | Biocomposites, Llc | Process for preparing high density mechanically resistant insoluble collagen material in pure and combined forms |
| US7276235B2 (en) | 1998-11-18 | 2007-10-02 | Zlb Behring Gmbh | Tissue glue with improved antiadhesive properties |
| US6200330B1 (en) | 1998-11-23 | 2001-03-13 | Theodore V. Benderev | Systems for securing sutures, grafts and soft tissue to bone and periosteum |
| DE19855890A1 (en) | 1998-12-03 | 2000-06-08 | Nerlich Michael | Porous composite matrix, its production and use |
| WO2000048837A1 (en) | 1999-02-16 | 2000-08-24 | Dek Printing Machines Limited | Apparatus and method for depositing a viscous material |
| US6264659B1 (en) | 1999-02-22 | 2001-07-24 | Anthony C. Ross | Method of treating an intervertebral disk |
| US6436143B1 (en) | 1999-02-22 | 2002-08-20 | Anthony C. Ross | Method and apparatus for treating intervertebral disks |
| DE19908628A1 (en) | 1999-02-27 | 2000-08-31 | Lurgi Zimmer Ag | Catalyst, process for its preparation and use of the catalyst |
| US6395327B1 (en) | 1999-03-12 | 2002-05-28 | Zimmer, Inc. | Enhanced fatigue strength orthopaedic implant with porous coating and method of making same |
| AU3556400A (en) | 1999-03-17 | 2000-10-04 | Novartis Ag | Pharmaceutical compositions |
| US6662805B2 (en) | 1999-03-24 | 2003-12-16 | The Johns Hopkins University | Method for composite cell-based implants |
| US6110210A (en) | 1999-04-08 | 2000-08-29 | Raymedica, Inc. | Prosthetic spinal disc nucleus having selectively coupled bodies |
| US6428576B1 (en) | 1999-04-16 | 2002-08-06 | Endospine, Ltd. | System for repairing inter-vertebral discs |
| US6370920B1 (en) | 1999-04-28 | 2002-04-16 | Alcatel | Apparatus to improve degree of cure for ultraviolet curable optical fiber coating by actively removing heat from the coating during irradiation |
| US6287340B1 (en) | 1999-05-14 | 2001-09-11 | Trustees Of Tufts College | Bioengineered anterior cruciate ligament |
| US6645947B1 (en) | 1999-05-20 | 2003-11-11 | Chitogenics, Inc. | Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins |
| WO2000073536A1 (en) | 1999-05-28 | 2000-12-07 | Henkel Kommanditgesellschaft Auf Aktien | Post-passivation of a phosphatized metal surface |
| US6472162B1 (en) | 1999-06-04 | 2002-10-29 | Thermogenesis Corp. | Method for preparing thrombin for use in a biological glue |
| DE19926083A1 (en) | 1999-06-08 | 2000-12-14 | Universitaetsklinikum Freiburg | Biological joint construct |
| US20040059416A1 (en) | 1999-06-22 | 2004-03-25 | Murray Martha M. | Biologic replacement for fibrin clot |
| US6333029B1 (en) | 1999-06-30 | 2001-12-25 | Ethicon, Inc. | Porous tissue scaffoldings for the repair of regeneration of tissue |
| US6632651B1 (en) | 1999-07-06 | 2003-10-14 | Ramot At Tel Aviv University Ltd. | Tissue maintenance system that applies rhythmic pulses of pressure |
| US6652872B2 (en) | 1999-07-06 | 2003-11-25 | Ramat At Tel Aviv University Ltd. | Scaffold formed of tissue treated to eliminate cellular and cytosolic elements |
| CA2344222C (en) | 1999-07-21 | 2008-05-13 | Imedex Biomateriaux | Adhesive protein foam for surgical and/or therapeutic uses |
| ES2239608T3 (en) | 1999-07-28 | 2005-10-01 | Interface Biotech A/S | IN VITRO REPAIR OF BONE AND / OR CARTILAGO DEFECTS. |
| GB9918884D0 (en) | 1999-08-10 | 1999-10-13 | Novarticulate Bv | Method and apparatus for delivering cement to bones |
| US6425919B1 (en) | 1999-08-18 | 2002-07-30 | Intrinsic Orthopedics, Inc. | Devices and methods of vertebral disc augmentation |
| US6280993B1 (en) | 1999-08-24 | 2001-08-28 | Ichiro Yamato | Gene encoding class I collagenase |
| US6620169B1 (en) | 1999-08-26 | 2003-09-16 | Spineology Group, Llc. | Tools and method for processing and injecting bone graft |
| US6322563B1 (en) | 1999-09-17 | 2001-11-27 | Genzyme Corporation | Small tissue and membrane fixation apparatus and methods for use thereof |
| GB9922872D0 (en) | 1999-09-28 | 1999-12-01 | Depuy Int Ltd | Bone tissue repair kit |
| US6528052B1 (en) | 2000-09-29 | 2003-03-04 | The Board Of Trustees Of The Leland Stanford Junior University | Method for in vivo ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling |
| US6579538B1 (en) | 1999-12-22 | 2003-06-17 | Acell, Inc. | Tissue regenerative compositions for cardiac applications, method of making, and method of use thereof |
| US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
| US6425704B2 (en) | 2000-01-07 | 2002-07-30 | Closure Medical Corporation | Adhesive applicators with improved applicator tips |
| US6626859B2 (en) | 2000-01-18 | 2003-09-30 | Coraflo Ltd. | High performance cannulas |
| US6447514B1 (en) | 2000-03-07 | 2002-09-10 | Zimmer | Polymer filled hip fracture fixation device |
| US6336930B1 (en) | 2000-03-07 | 2002-01-08 | Zimmer, Inc. | Polymer filled bone plate |
| US6332894B1 (en) | 2000-03-07 | 2001-12-25 | Zimmer, Inc. | Polymer filled spinal fusion cage |
| DE10013223C2 (en) | 2000-03-13 | 2002-07-18 | Co Don Ag | Process for the in vitro production of three-dimensional, vital cartilage or bone tissue and its use as a transplant material |
| JP4871476B2 (en) | 2000-03-13 | 2012-02-08 | バイオコンパティブルズ ユーケー リミテッド | Embolization composition |
| US6652883B2 (en) | 2000-03-13 | 2003-11-25 | Biocure, Inc. | Tissue bulking and coating compositions |
| US6626945B2 (en) | 2000-03-14 | 2003-09-30 | Chondrosite, Llc | Cartilage repair plug |
| US6632246B1 (en) | 2000-03-14 | 2003-10-14 | Chondrosite, Llc | Cartilage repair plug |
| DE20019809U1 (en) | 2000-05-31 | 2001-07-12 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 80636 München | Cartilage replacement and biomatrix for the cultivation of cells |
| US6533817B1 (en) | 2000-06-05 | 2003-03-18 | Raymedica, Inc. | Packaged, partially hydrated prosthetic disc nucleus |
| US6991652B2 (en) | 2000-06-13 | 2006-01-31 | Burg Karen J L | Tissue engineering composite |
| EP1296724A1 (en) | 2000-06-22 | 2003-04-02 | Sam L. Austin | Bioadhesive composition and methods of preparation and use |
| US6921532B1 (en) | 2000-06-22 | 2005-07-26 | Spinal Restoration, Inc. | Biological Bioadhesive composition and methods of preparation and use |
| US9387094B2 (en) | 2000-07-19 | 2016-07-12 | Warsaw Orthopedic, Inc. | Osteoimplant and method of making same |
| DE60141653D1 (en) | 2000-07-21 | 2010-05-06 | Spineology Group Llc | A STRONG, POROUS NET BAG DEVICE AND ITS USE IN BONE SURGERY |
| US6653062B1 (en) | 2000-07-26 | 2003-11-25 | Wisconsin Alumni Research Foundation | Preservation and storage medium for biological materials |
| ATE420947T1 (en) | 2000-07-29 | 2009-01-15 | Smith & Nephew | TISSUE IMPLANT FOR RESTORING CARTILAGE TISSUE |
| US7186419B2 (en) | 2000-08-25 | 2007-03-06 | Contura Sa | Polyacrylamide hydrogel for arthritis |
| MY130475A (en) | 2000-08-25 | 2007-06-29 | Contura As | Polyacrylamide hydrogel and its use as an endoprosthesis |
| EP1315470B1 (en) | 2000-08-28 | 2009-07-15 | Disc Dynamics, Inc. | System for mammalian joint resurfacing |
| US6620196B1 (en) | 2000-08-30 | 2003-09-16 | Sdgi Holdings, Inc. | Intervertebral disc nucleus implants and methods |
| EP1333870A2 (en) | 2000-09-20 | 2003-08-13 | Regeneration Technologies, Inc. | Method of preparing and processing transplant tissue |
| US6610033B1 (en) | 2000-10-13 | 2003-08-26 | Incept, Llc | Dual component medicinal polymer delivery system and methods of use |
| WO2002039948A2 (en) | 2000-11-14 | 2002-05-23 | N.V.R. Labs Inc. | Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants |
| JP2002233567A (en) | 2000-12-06 | 2002-08-20 | Mitsuo Ochi | Tissue equivalent for transplantation and method for producing the same |
| DE10061195B4 (en) | 2000-12-08 | 2004-12-02 | 3M Espe Ag | Use of impression materials for the production of treatment devices |
| CA2365376C (en) | 2000-12-21 | 2006-03-28 | Ethicon, Inc. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
| US6852330B2 (en) | 2000-12-21 | 2005-02-08 | Depuy Mitek, Inc. | Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
| US6890295B2 (en) | 2002-10-31 | 2005-05-10 | Medtronic, Inc. | Anatomical space access tools and methods |
| US6697143B2 (en) | 2001-02-12 | 2004-02-24 | Viztec, Inc. | Electrooptical displays constructed with polymerization initiating and enhancing elements positioned between substrates |
| US7666192B2 (en) | 2001-02-16 | 2010-02-23 | Kci Licensing, Inc. | Skin grafting devices and methods |
| US7651507B2 (en) | 2003-03-03 | 2010-01-26 | Kci Licensing, Inc. | Tissue processing system |
| US7544196B2 (en) | 2001-02-20 | 2009-06-09 | Orthovita, Inc. | System and kit for delivery of restorative materials |
| WO2002067856A2 (en) | 2001-02-23 | 2002-09-06 | University Of Massachusetts | Injection molding of living tissues |
| WO2002067812A2 (en) | 2001-02-23 | 2002-09-06 | University Of Massachusetts | Tympanic membrane patch |
| US6743232B2 (en) | 2001-02-26 | 2004-06-01 | David W. Overaker | Tissue scaffold anchor for cartilage repair |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| US20040151705A1 (en) | 2002-03-22 | 2004-08-05 | Shuichi Mizuno | Neo-cartilage constructs and a method for preparation thereof |
| US6949252B2 (en) | 2001-03-23 | 2005-09-27 | Histogenics, Corp. | Method for preparing an implantable multilayer tissue construct |
| WO2002080991A2 (en) | 2001-04-09 | 2002-10-17 | Medtronic, Inc. | System for the production of autologous platelet gel |
| US6942880B1 (en) | 2001-04-09 | 2005-09-13 | Medtronic, Inc. | Autologous platelet gel having beneficial geometric shapes and methods of making the same |
| AU2002258913A1 (en) | 2001-04-23 | 2002-11-05 | Wisconsin Alumni Research Foundation | Bifunctional-modified hydrogels |
| DE60121826T2 (en) | 2001-05-09 | 2007-02-22 | Baxter International Inc., Deerfield | FIBRIN MATERIAL AND METHOD FOR ITS MANUFACTURE AND USE |
| KR20020088848A (en) | 2001-05-21 | 2002-11-29 | (주)코아바이오텍 | Cell Culture Tube and Multiple Roller Tube Cell Culture System Using The Same |
| US20020183858A1 (en) | 2001-06-05 | 2002-12-05 | Contiliano Joseph H. | Attachment of absorbable tissue scaffolds to scaffold fixation devices |
| US20050079159A1 (en) | 2001-06-13 | 2005-04-14 | Massachusetts Instiute Of Technology | In vivo bioreactors |
| KR20020095842A (en) | 2001-06-16 | 2002-12-28 | 삼성전자 주식회사 | Ashing apparatus of semiconductor |
| US6626950B2 (en) | 2001-06-28 | 2003-09-30 | Ethicon, Inc. | Composite scaffold with post anchor for the repair and regeneration of tissue |
| CA2447818C (en) | 2001-07-02 | 2011-01-04 | Nordmark Arzneimittel Gmbh & Co. Kg | Method for purifying an enzyme and purified enzyme produced according to this method, as well as use of the enzyme |
| FR2827290B1 (en) | 2001-07-13 | 2004-07-09 | Pierre Jouan Biotechnologies Sa | METHOD FOR OBTAINING A PROTEIN FRACTION ENRICHED IN ACTIVATED FORM TGF-BETA, PROTEIN FRACTION AND THERAPEUTIC APPLICATIONS |
| IL144446A0 (en) | 2001-07-19 | 2002-05-23 | Prochon Biotech Ltd | Plasma protein matrices and methods for their preparation |
| CN1296393C (en) | 2001-08-25 | 2007-01-24 | 康特拉有限公司 | Temperature Control Method for Homogeneous Polymer Preparation |
| EP1432371B1 (en) | 2001-10-02 | 2009-07-08 | Rex Medical, L.P. | Spinal implant |
| JP4451658B2 (en) | 2001-10-18 | 2010-04-14 | ライフセル コーポレーション | Tissue and organ remodeling |
| US7160725B2 (en) * | 2001-11-13 | 2007-01-09 | Curis, Inc. | Hedgehog signaling promotes the formation of three dimensional cartilage matrices |
| EP1460982A4 (en) | 2001-11-16 | 2010-04-14 | Biocure Inc | Methods for initiating in situ formation of hydrogels |
| JP2003180699A (en) | 2001-12-20 | 2003-07-02 | Kyocera Corp | Articular cartilage treatment implant |
| NZ534428A (en) | 2002-01-31 | 2006-12-22 | Asahi Techno Glass Corp | A cryopreservation method for primate embryonic stem cells using a cryopreservation medium comprising a cryoprotectant at a concentration of from 12% (w/v) to 50% (w/v) |
| US20020106625A1 (en) | 2002-02-07 | 2002-08-08 | Hung Clark T. | Bioreactor for generating functional cartilaginous tissue |
| US7042803B2 (en) | 2002-02-08 | 2006-05-09 | Input/Output Inc. | Marine seismic source towing apparatus and method |
| AU2002233088A1 (en) | 2002-02-15 | 2003-09-04 | Ocean Nutrition Canada Limited | Shark cartilage extracts and use thereof for immunomodulation |
| US6740186B2 (en) | 2002-02-20 | 2004-05-25 | Zimmer Technology, Inc. | Method of making an orthopeadic implant having a porous metal surface |
| TWI290055B (en) | 2002-03-14 | 2007-11-21 | Tissuetech Inc | Amniotic membrane covering for a tissue surface and devices facilitating fastening of membranes |
| US7537780B2 (en) | 2002-03-22 | 2009-05-26 | Histogenics Corporation | Method for preparing and implanting a cartilage construct to treat cartilage lesions |
| US7468192B2 (en) | 2002-03-22 | 2008-12-23 | Histogenics Corporation | Method for repair of cartilage lesions |
| US20030187515A1 (en) | 2002-03-26 | 2003-10-02 | Hariri Robert J. | Collagen biofabric and methods of preparing and using the collagen biofabric |
| AU2003228808A1 (en) | 2002-05-02 | 2003-11-17 | Regents Of The University Of Minnesota | Fibrin-based biomatrix |
| GB0211963D0 (en) | 2002-05-24 | 2002-07-03 | British American Tobacco Co | An exposure device |
| US7299805B2 (en) | 2002-06-07 | 2007-11-27 | Marctec, Llc | Scaffold and method for implanting cells |
| US7166133B2 (en) | 2002-06-13 | 2007-01-23 | Kensey Nash Corporation | Devices and methods for treating defects in the tissue of a living being |
| US6797006B2 (en) | 2002-06-18 | 2004-09-28 | Zimmer Technology, Inc. | Porous unicondylar knee |
| US6938939B2 (en) | 2002-06-26 | 2005-09-06 | Rbw Industries, Inc. | Room expansion system |
| DE10261126A1 (en) | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Storage-stable, liquid fibrinogen formulation |
| US7494460B2 (en) | 2002-08-21 | 2009-02-24 | Medtronic, Inc. | Methods and apparatus providing suction-assisted tissue engagement through a minimally invasive incision |
| AU2003257684A1 (en) | 2002-08-23 | 2004-03-11 | Asahi Medical Co., Ltd. | Fibrin-containing composition |
| US20040126881A1 (en) | 2002-09-06 | 2004-07-01 | Vincent Ronfard | Fibrin cell supports and methods of use thereof |
| US7744651B2 (en) | 2002-09-18 | 2010-06-29 | Warsaw Orthopedic, Inc | Compositions and methods for treating intervertebral discs with collagen-based materials |
| US20040054414A1 (en) | 2002-09-18 | 2004-03-18 | Trieu Hai H. | Collagen-based materials and methods for augmenting intervertebral discs |
| US6840960B2 (en) | 2002-09-27 | 2005-01-11 | Stephen K. Bubb | Porous implant system and treatment method |
| US7666134B2 (en) | 2002-09-28 | 2010-02-23 | Kci Licensing, Inc. | System and method for transplantation of dermal tissue |
| AU2003265103A1 (en) | 2002-09-30 | 2004-04-19 | Bioland Ltd. | Dermal substitute consisting of amnion and biodegradable polymer, the preparation method and the use thereof |
| US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
| US20040078090A1 (en) | 2002-10-18 | 2004-04-22 | Francois Binette | Biocompatible scaffolds with tissue fragments |
| US7824701B2 (en) | 2002-10-18 | 2010-11-02 | Ethicon, Inc. | Biocompatible scaffold for ligament or tendon repair |
| IL153699A (en) | 2002-12-26 | 2008-11-26 | Prochon Biotech Ltd | Bone graft composite |
| US7115100B2 (en) | 2002-11-15 | 2006-10-03 | Ethicon, Inc. | Tissue biopsy and processing device |
| US6921633B2 (en) | 2002-11-18 | 2005-07-26 | Biolife Solutions Incorporated | Methods and compositions for the preservation of cells, tissues or organs in the vitreous state |
| US20040230309A1 (en) | 2003-02-14 | 2004-11-18 | Depuy Spine, Inc. | In-situ formed intervertebral fusion device and method |
| JP2006524502A (en) | 2003-02-28 | 2006-11-02 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | Breast cancer expression profile and usage |
| GB0304799D0 (en) | 2003-03-03 | 2003-04-09 | Glaxosmithkline Biolog Sa | Novel method |
| US20040175690A1 (en) | 2003-03-03 | 2004-09-09 | Kci Licensing, Inc. | Tissue harvesting device and method |
| US20050222687A1 (en) | 2004-04-02 | 2005-10-06 | Gordana Vunjak-Novakovic | Cartilage implant assembly and method for implantation |
| US20050064042A1 (en) | 2003-04-29 | 2005-03-24 | Musculoskeletal Transplant Foundation | Cartilage implant plug with fibrin glue and method for implantation |
| US7067123B2 (en) | 2003-04-29 | 2006-06-27 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
| US20050123520A1 (en) | 2003-05-05 | 2005-06-09 | Eavey Roland D. | Generation of living tissue in vivo using a mold |
| US20090291112A1 (en) | 2003-05-16 | 2009-11-26 | Truncale Katherine G | Allograft osteochondral plug combined with cartilage particle mixture |
| US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
| US7488348B2 (en) | 2003-05-16 | 2009-02-10 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
| KR20060031808A (en) | 2003-06-11 | 2006-04-13 | 오스테오테크, 인코포레이티드 | Osteoimplants and methods for their manufacture |
| EP1635887A2 (en) | 2003-06-12 | 2006-03-22 | Interface Biotech A/S | A method for cell implantation |
| US20050124038A1 (en) | 2003-07-14 | 2005-06-09 | Pharmacia Corporation | Transfection of cartilage and matrices thereof in vitro |
| JP4339855B2 (en) | 2003-07-31 | 2009-10-07 | 日本メディカルマテリアル株式会社 | How to make an artificial joint |
| GB0318125D0 (en) | 2003-08-01 | 2003-09-03 | Inst Of Cancer Res The | Apparatus and methods for tissue preparation |
| WO2005016123A2 (en) | 2003-08-11 | 2005-02-24 | Chudik Steven C M D | Devices and methods used for shoulder replacement |
| US10583220B2 (en) | 2003-08-11 | 2020-03-10 | DePuy Synthes Products, Inc. | Method and apparatus for resurfacing an articular surface |
| EP1662973A4 (en) | 2003-08-20 | 2011-07-20 | Histogenics Corp | Acellular matrix implanted into an articular cartilage or osteochondral lesion protected with a biodegradable polymer modified to have extended polymerization time and methods for preparation and use thereof |
| US7217294B2 (en) | 2003-08-20 | 2007-05-15 | Histogenics Corp. | Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and method for use thereof |
| US8043614B2 (en) | 2004-03-09 | 2011-10-25 | Ahlfors Jan-Eric W | Autogenic living scaffolds and living tissue matrices: methods and uses thereof |
| US7897384B2 (en) | 2003-09-08 | 2011-03-01 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
| US7375077B2 (en) | 2003-09-19 | 2008-05-20 | The Board Of Trustees Of The University Of Illinois | In vivo synthesis of connective tissues |
| ATE450601T1 (en) | 2003-09-19 | 2009-12-15 | Univ Keio | COMPOSITION FOR COATING A SUPPORT FOR PRODUCING A CELL LAYER, SUPPORT FOR PRODUCING A CELL LAYER AND METHOD FOR PRODUCING A CELL LAYER |
| EP1529543A1 (en) | 2003-11-04 | 2005-05-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of a hydrogel for culturing chondrocytes |
| JP2007513083A (en) | 2003-11-10 | 2007-05-24 | アンジオテック インターナショナル アーゲー | Medical implants and fiber inducers |
| US7316822B2 (en) | 2003-11-26 | 2008-01-08 | Ethicon, Inc. | Conformable tissue repair implant capable of injection delivery |
| US8673021B2 (en) | 2003-11-26 | 2014-03-18 | Depuy Mitek, Llc | Arthroscopic tissue scaffold delivery device |
| US7901461B2 (en) | 2003-12-05 | 2011-03-08 | Ethicon, Inc. | Viable tissue repair implants and methods of use |
| WO2005061019A2 (en) | 2003-12-10 | 2005-07-07 | Cellular Bioengineering, Inc. (Cbi) | Methods and composition for soft tissue feature reconstruction |
| EP2338442B1 (en) | 2003-12-11 | 2013-01-30 | Isto Technologies Inc. | Particulate cartilage system |
| DK1722834T3 (en) | 2003-12-22 | 2012-10-22 | Regentis Biomaterials Ltd | Matrix, which includes naturally occurring cross-linked protein skeleton |
| US20050137600A1 (en) | 2003-12-23 | 2005-06-23 | Jacobs Andrew M. | Articular cartilage repair implant delivery device and method of use |
| KR100531922B1 (en) | 2003-12-23 | 2005-11-29 | 주식회사 셀론텍 | a composition for cartilage therapeutics and a using method thereof |
| US6997381B2 (en) | 2003-12-24 | 2006-02-14 | Michael Arnouse | Dual-sided smart card reader |
| US7500947B2 (en) | 2004-01-29 | 2009-03-10 | Cannonflow, Inc. | Atraumatic arthroscopic instrument sheath |
| US7435214B2 (en) | 2004-01-29 | 2008-10-14 | Cannuflow, Inc. | Atraumatic arthroscopic instrument sheath |
| US7445596B2 (en) | 2004-01-29 | 2008-11-04 | Cannuflow, Inc. | Atraumatic arthroscopic instrument sheath |
| US7413542B2 (en) | 2004-01-29 | 2008-08-19 | Cannuflow, Inc. | Atraumatic arthroscopic instrument sheath |
| US11395865B2 (en) | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
| EP1753860B1 (en) | 2004-02-20 | 2012-04-11 | Isto Technologies Inc. | Intervertebral disc repair and methods therefor |
| US20060275273A1 (en) | 2004-02-20 | 2006-12-07 | Seyedin Mitchell S | Intervertebral Disc Repair, Methods and Devices Therefor |
| US8597352B2 (en) | 2004-03-03 | 2013-12-03 | Schwartz Biomedical, Llc | Articular cartilage fixation device and method |
| US20050196460A1 (en) | 2004-03-08 | 2005-09-08 | Malinin Theodore I. | Particulate cartilage compositions, processes for their preparation and methods for regenerating cartilage |
| US20080039940A1 (en) | 2004-03-11 | 2008-02-14 | Kouji Hashimoto | Biological Tissue Sheet, Method Of Forming The Same And Transplantation Method By Using The Sheet |
| US8029511B2 (en) | 2004-03-22 | 2011-10-04 | Disc Dynamics, Inc. | Multi-stage biomaterial injection system for spinal implants |
| US20070292945A1 (en) | 2004-03-25 | 2007-12-20 | Lin Wenglong R | Cell Culture Apparatus and Methods |
| US20060041270A1 (en) | 2004-05-07 | 2006-02-23 | Jay Lenker | Medical access sheath |
| JP2007536935A (en) | 2004-05-14 | 2007-12-20 | ベクトン・ディキンソン・アンド・カンパニー | Cell culture environment for serum-free growth of mesenchymal stem cells |
| US20050287223A1 (en) | 2004-06-23 | 2005-12-29 | Peyman Gholam A | Use of amniotic membrane as biocompatible devices |
| US20050288796A1 (en) | 2004-06-23 | 2005-12-29 | Hani Awad | Native soft tissue matrix for therapeutic applications |
| EP1773358A2 (en) | 2004-06-29 | 2007-04-18 | BioCure, Inc. | Biomaterial |
| US7740660B2 (en) | 2004-06-29 | 2010-06-22 | Spine Wave, Inc. | Methods for treating defects and injuries of an intervertebral disc |
| WO2006017176A2 (en) | 2004-07-09 | 2006-02-16 | William Marsh Rice University | Scaffoldless constructs for tissue engineering of articular cartilage |
| JP4949241B2 (en) | 2004-07-12 | 2012-06-06 | イスト・テクノロジーズ・インコーポレイテッド | Tissue matrix system |
| US8512730B2 (en) | 2004-07-12 | 2013-08-20 | Isto Technologies, Inc. | Methods of tissue repair and compositions therefor |
| US20070213660A1 (en) | 2004-10-29 | 2007-09-13 | Mark Richards | Fibrin sealant delivery device including pressure monitoring, and method and kits thereof |
| US8419722B2 (en) | 2004-10-29 | 2013-04-16 | Spinal Restoration, Inc. | Apparatus and method for injection of fibrin sealant in spinal applications |
| US8357147B2 (en) | 2005-08-17 | 2013-01-22 | Spinal Restoration, Inc. | Method for repairing intervertebral discs |
| US20090181892A1 (en) | 2004-07-16 | 2009-07-16 | Spinal Restoration, Inc. | Methods and kits for treating joints and soft tissues |
| US20090181093A1 (en) | 2004-07-16 | 2009-07-16 | Spinal Restoration, Inc. | Methods for treating soft tissue damage associated with a surgical procedure |
| US20090181092A1 (en) | 2004-07-16 | 2009-07-16 | Spinal Restoration, Inc. | Methods for Treating Joints and Discs with a Carrier Matrix and Cells |
| US7335508B2 (en) | 2004-07-22 | 2008-02-26 | Prochon Biotech Ltd. | Porous plasma protein matrices and methods for preparation thereof |
| GB0421298D0 (en) | 2004-09-24 | 2004-10-27 | Univ Bristol | Cellular bandage |
| US8017394B2 (en) | 2004-10-01 | 2011-09-13 | Isto Technologies, Inc. | Method for chondrocyte expansion with phenotype retention |
| US7273756B2 (en) | 2004-10-01 | 2007-09-25 | Isto Technologies, Inc. | Method for chondrocyte expansion with phenotype retention |
| US7618410B2 (en) | 2004-10-05 | 2009-11-17 | Cardia Access, Inc. | Devices and methods for access through a tissue wall |
| US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
| US20060078872A1 (en) | 2004-10-12 | 2006-04-13 | Atsushi Taguchi | Cell-preservation liquid |
| AU2005301150B2 (en) | 2004-10-18 | 2011-02-03 | Covidien Lp | Apparatus for applying wound treatment material using tissue-penetrating needles |
| WO2006050213A2 (en) | 2004-10-29 | 2006-05-11 | Michalow Alexander E | Methods of promoting healing of cartilage defects and method of causing stem cells to differentiate by the articular chondrocyte pathway |
| US9981063B2 (en) | 2004-11-24 | 2018-05-29 | Mayo Foundation For Medical Education And Research | Biosynthetic composite for osteochondral defect repair |
| US8460178B2 (en) | 2004-11-30 | 2013-06-11 | Atul Kumar | Method and system for minimizing leakage of a distending medium during endoscopic procedures |
| US20090155229A1 (en) | 2004-12-06 | 2009-06-18 | Avner Yayon | Chondrocyte-based implant for the delivery of therapeutic agents |
| US20060171930A1 (en) | 2004-12-21 | 2006-08-03 | Agnieszka Seyda | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same |
| US20060153815A1 (en) | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
| KR20070093991A (en) | 2005-01-14 | 2007-09-19 | 아르브라스트 가부시키가이샤 | Sheet-like composition using amnion and its manufacturing method |
| EP1850661A2 (en) | 2005-02-22 | 2007-11-07 | Interface Multigrad Technology (IMT) Ltd. | Preserved viable cartilage, method for its preservation, and system and devices used therefor |
| JP2006230749A (en) | 2005-02-25 | 2006-09-07 | Kaneka Corp | Material for fixing prosthesis to cartilage tissue |
| US20070041952A1 (en) | 2005-04-18 | 2007-02-22 | Duke University | Three-dimensional fiber scaffolds for tissue engineering |
| US20060251631A1 (en) | 2005-05-05 | 2006-11-09 | Isto Technologies, Inc. | Treatment of joint disease, methods and apparatuses therefor |
| US20060264966A1 (en) | 2005-05-12 | 2006-11-23 | Med Institute, Inc. | Vertebroplasty leak prevention sleeve and method |
| US20070038299A1 (en) | 2005-08-12 | 2007-02-15 | Arthrotek, Inc | Multilayer microperforated implant |
| JP5292533B2 (en) | 2005-08-26 | 2013-09-18 | ジンマー・インコーポレイテッド | Implant and joint disease treatment, replacement and treatment methods |
| KR20080065606A (en) | 2005-09-02 | 2008-07-14 | 인터페이스 바이오텍 에이/에스 | Cell transplant method |
| US8158141B2 (en) | 2005-11-09 | 2012-04-17 | Paul Hong-Dze Chen | Cell transplant device for treatment of corneal wound |
| EP2264149A1 (en) | 2005-11-10 | 2010-12-22 | Carticure Ltd. | Method for non-autologous cartilage regeneration |
| EP1788077B8 (en) | 2005-11-18 | 2016-10-19 | LifeScan, Inc. | A method for creating cell clusters |
| US8444968B2 (en) | 2005-12-07 | 2013-05-21 | Isto Technologies, Inc. | Cartilage repair methods |
| US8524885B2 (en) | 2006-03-07 | 2013-09-03 | Prochon Biotech Ltd. | Hydrazido derivatives of hyaluronic acid |
| EP2007881A4 (en) | 2006-04-05 | 2009-07-08 | Univ Rice William M | TISSUE ENGINEERING USING HUMAN EMBRYONIC STEM CELLS |
| US20070250164A1 (en) | 2006-04-21 | 2007-10-25 | Biomet Manufacturing Corp. | Method for grafting whole superficial articular cartilage |
| US20070299517A1 (en) | 2006-06-21 | 2007-12-27 | Howmedica Osteonics Corp. | Articular cartilage implant |
| WO2008019127A2 (en) | 2006-08-04 | 2008-02-14 | Stb Lifesaving Technologies, Inc. | Solid dressing for treating wounded tissue |
| US20080039954A1 (en) | 2006-08-08 | 2008-02-14 | Howmedica Osteonics Corp. | Expandable cartilage implant |
| US8449622B2 (en) | 2006-09-11 | 2013-05-28 | Warsaw Orthopedic, Inc. | Multi-phase osteochondral implantable device |
| US20080154233A1 (en) | 2006-12-20 | 2008-06-26 | Zimmer Orthobiologics, Inc. | Apparatus for delivering a biocompatible material to a surgical site and method of using same |
| US7720533B2 (en) | 2006-12-20 | 2010-05-18 | Zimmer Orthobiologicals, Inc. | Apparatus and method for delivering a biocompatible material to a surgical site |
| US8163549B2 (en) | 2006-12-20 | 2012-04-24 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
| KR101424308B1 (en) | 2006-12-22 | 2014-08-01 | 라보라뜨와 메디동 소시에떼아노님 | In situ system for intra-articular chondral and osseous tissue repair |
| WO2008081463A2 (en) | 2007-01-04 | 2008-07-10 | Hepacore Ltd. | Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof |
| US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
| US20090012629A1 (en) | 2007-04-12 | 2009-01-08 | Isto Technologies, Inc. | Compositions and methods for tissue repair |
| EP2224884A2 (en) | 2007-12-05 | 2010-09-08 | Musculoskeletal Transplant Foundation | Cancellous bone implant for cartilage repair |
| EP2265220A1 (en) | 2008-03-05 | 2010-12-29 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
| US20100168856A1 (en) | 2008-12-31 | 2010-07-01 | Howmedica Osteonics Corp. | Multiple piece tissue void filler |
| US20100274362A1 (en) | 2009-01-15 | 2010-10-28 | Avner Yayon | Cartilage particle tissue mixtures optionally combined with a cancellous construct |
| BRPI1016020B8 (en) * | 2009-06-29 | 2022-05-10 | Aesculap Ag | surgical line comprising cells and their production method |
| US20140178343A1 (en) | 2012-12-21 | 2014-06-26 | Jian Q. Yao | Supports and methods for promoting integration of cartilage tissue explants |
-
2013
- 2013-03-13 US US13/799,452 patent/US20140178343A1/en not_active Abandoned
-
2014
- 2014-06-09 US US14/299,314 patent/US10167447B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050032015A1 (en) * | 2003-08-07 | 2005-02-10 | Mcsurdy David W. | System and method for palatal expansion |
| US20070184550A1 (en) * | 2005-08-02 | 2007-08-09 | Satoshi Miyauchi | Artificial cartilage tissue and production method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9138318B2 (en) | 2007-04-12 | 2015-09-22 | Zimmer, Inc. | Apparatus for forming an implant |
| US10167447B2 (en) | 2012-12-21 | 2019-01-01 | Zimmer, Inc. | Supports and methods for promoting integration of cartilage tissue explants |
| US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
| US11806443B2 (en) | 2015-08-19 | 2023-11-07 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
| US11938245B2 (en) | 2015-08-19 | 2024-03-26 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
Also Published As
| Publication number | Publication date |
|---|---|
| US20140335612A1 (en) | 2014-11-13 |
| US10167447B2 (en) | 2019-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Woodfield et al. | Scaffolds for tissue engineering of cartilage | |
| Sharma et al. | Engineering structurally organized cartilage and bone tissues | |
| Cancedda et al. | Tissue engineering and cell therapy of cartilage and bone | |
| EP1649875B1 (en) | Method of constructing artificial joint | |
| Freed et al. | Joint resurfacing using allograft chondrocytes and synthetic biodegradable polymer scaffolds | |
| JP4406283B2 (en) | Tissue regeneration substrate, transplant material, and production method thereof | |
| Li et al. | A biphasic scaffold based on silk and bioactive ceramic with stratified properties for osteochondral tissue regeneration | |
| US20110293584A1 (en) | Tissue Regeneration | |
| JP2003510108A (en) | Biological joint structures | |
| CN101589139A (en) | Artificial cartilage containing chondrocytes obtained from costal cartilage and method for producing same | |
| US10167447B2 (en) | Supports and methods for promoting integration of cartilage tissue explants | |
| JP2016028756A (en) | Scaffolds | |
| Kunisch et al. | StarPEG/heparin-hydrogel based in vivo engineering of stable bizonal cartilage with a calcified bottom layer | |
| Kean et al. | The role of biomaterials in the treatment of meniscal tears | |
| KR20130111347A (en) | Cultured cartilage tissue material | |
| Schagemann et al. | Morphology and function of ovine articular cartilage chondrocytes in 3-d hydrogel culture | |
| JP2004357694A (en) | Method for producing tissue plug | |
| US8431399B2 (en) | Method to restore cartilaginous phenotype of chondrocytes after cultured and expanded in vitro | |
| US11786636B2 (en) | Methods for complex tissue engineering | |
| US20150344847A1 (en) | Method For Production Of Large Numbers Of Cartilage Cells With Phenotype Retention | |
| US20230122977A1 (en) | Regenerative Tissue-Mimetic Multilayer Fused Microgel-Cell Construct | |
| RU2335538C2 (en) | Organization of cells similar to tissue and macroscopical designs similar to tissue obtained by means of culture of macromass of cells and method of macromass culture | |
| Martin et al. | Repair of osteochondral lesions | |
| Murata | Cartilage (and Subchondral Bone) | |
| Garner | Tissue engineering and the trauma surgeon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: ZIMMER, INC., INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YAO, JIAN Q;WANG, HALI;SIGNING DATES FROM 20130809 TO 20130820;REEL/FRAME:031636/0482 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |